Stockwinners Market Radar for September 13, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:55 EDT Sunlight Financial CEO buys 85K shares of common stock - In a regulatory filing, Sunlight Financial disclosed that its CEO Matthew Potere bought 85K shares of common stock on September 10th in a total transaction size of $460K. Shares of Sunlight Financial are up 1.5% in after-hours trading at $5.35 per share.

19:01 EDT Roy Hill buys Wabtec's FLXdrive battery-electric locomotive - Roy Hill "announced the purchase of Wabtec's FLXdrive battery-electric locomotive, the world's first 100-percent battery, heavy-haul locomotive for the region and the mining industry. Roy Hill will receive the newest version of the FLXdrive battery-electric locomotive in 2023 with an energy capacity of 7 megawatt hours (MWh). It is an upgrade from the 2.4-MWh prototype that was successfully tested in revenue service with a Class 1 railroad in the United States earlier this year. Based on the route and Roy Hill's rail operations, the FLXdrive is anticipated to reduce the company's fuel costs and emissions in percentage by double digits per train. The ongoing use of the FLXdrive will also reduce ongoing operational costs through maintenance spend."

18:54 EDT Matrix Service CEO says pace of awards begun to accelerate - CEO John Hewitt says: "Fourth quarter revenue in all three segments increased over the third quarter, and the pace of awards has begun to accelerate in the new fiscal year. This acceleration of awards reflects the growing confidence of our customers and improvement in our end-markets. Small- to mid-size project award activity is increasing across all our segments, and we expect to benefit from increased investment across the clean energy markets including renewable fuels, battery storage, and hydrogen, along with pent up demand in our traditional energy and industrial markets. Importantly, we are well positioned to execute on these opportunities due to our strong financial position. In addition, following reductions in overhead achieved over the last 18 months, we have begun a review of our organizational structure, with the support of a third party, to align the organization with the strategic direction of the business and changes in our end markets. We expect this effort will maximize our organizational structure, leading to improved project capture rates and bottom-line results as we move through fiscal 2022."

18:29 EDT Lockheed Martin, Pentagon agree to F-35 sustainment contracts - The F-35 Joint Program Office awarded the Lockheed Martin industry team annualized contracts covering fiscal years 2021-2023 to support operations and sustainment of the global F-35 fleet, supporting mission readiness and further reducing costs. The annual contracts fund critical sustainment activities for aircraft currently in the fleet and build enterprise capacity to support the future fleet of more than 3,000 F-35 aircraft. This includes industry sustainment experts supporting base and depot maintenance, pilot and maintainer training, and sustaining engineering for the U.S. and our allies across the globe. It also covers fleet-wide data analytics and supply chain management for part repair and replenishment to enhance overall supply availability for the fleet. The FY2021-2023 contracts represent a planned next step in further reducing overall operations and support costs for the F-35 program, which are shared between government and industry. Lockheed Martin has reduced our cost per flight hour by 44% in the past five years, with a forecasted reduction of an additional 40% in the next five years. The cost savings in the FY21-23 annualized sustainment contracts support Lockheed Martin's efforts to realize these goals. The savings will be achieved through improved cost and velocity in our supply chain, continued reliability improvements, and greater manpower efficiencies to provide product support solutions across the growing, global fleet. We remain committed to partnering with our customers and teammates to drive F-35 sustainment costs down.

18:23 EDT Barrick Gold CEO: We have huge opportunities in Nevada - In an interview on CNBC's Mad Money, Mark Bristow said Barrick is returning capital to shareholders and investing in the future. The company has moved from massive debt to no debt, net cash, he noted. "This is a long term game, a stable insurance policy to investors," he said. Gold takes the risk out of any investment long term, he added.

18:13 EDT Microsoft EVP Hogan sells 20,000 common shares - In a regulatory filing, Microsoft EVP of Human Resources Kathleen Hogan disclosed the sale of 20,000 common shares of the company on September 10 at a price of $298.677 per share.

17:43 EDT Quanterix gets label expansion on EUA for Simoa COVID antigen test - Quanterix announced that the FDA has expanded the Emergency Use Authorization label for its Simoa SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab and saliva samples, and for asymptomatic serial testing with nasal swab samples. The expanded label establishes this test as the first antigen test authorized for use with saliva samples. The test is validated to detect all Variants of Concern currently designated by the Centers for Disease Control and is the first non-NGS test validated and independently confirmed to detect the highly transmissible Delta variant in sequence-confirmed clinical samples. The test can be run on Quanterix' Simoa HD-X Analyze, a fully automated high-throughput immunoassay instrument.

17:37 EDT Lockheed Martin awarded $2.01B Navy contract - Lockheed Martin was awarded a $2.01B cost-plus-fixed-fee, cost-plus-incentive-fee, fixed-price-incentive-fee contract definitization. This contract provides logistics support, to include ground maintenance activities, action request resolution, depot activities, automatic logistics information system operations and maintenance, reliability and maintainability, supply chain management, pilot training, maintainer training, and training system sustainment in support of delivered F-35 Lightning II Joint Strike Fighter air systems for the Navy, Marine Corps, Air Force, Foreign Military Sales, or FMS, customers and non-U.S. Department of Defense, or DOD, participants. Work is expected to be completed in December. FY21 operation and maintenance funds in the amount of $822.01M; FY21 operation and maintenance funds in the amount of $382.22M; FY21 operation and maintenance funds in the amount of $176.73M; FY21 aircraft procurement funds in the amount of $2.29M; FY21 aircraft procurement funds in the amount of $1.21M; FMS funds in the amount of $217.26M and non-U.S. DOD participant funds in the amount of $412.35M will be obligated at time of award, $1.38B of which will expire at the end of the current fiscal year. This contract was not competitively procured pursuant to Defense Federal Acquisition Regulation 6.302-1. The Naval Air Systems Command is the contracting activity.

17:33 EDT U.S. Patent and Trademark Office rejects Axonics' challenge to Medtronic patents - Medtronic plc (MDT), announced it has won three additional important victories in a dispute over its intellectual property,IP, for its sacral neuromodulation device family, the InterStim( systems. The Patent Trial and Appeal Board, PTAB, of the U.S. Patent and Trademark Office rejected Axonics' (AXNX) attempt to invalidate three Medtronic patents in its IP infringement lawsuit. Significantly, this victory is in addition to the PTAB's affirmation of Medtronic's U.S. Patent No. 9,463,324 in September 2020, which protects key technology related to implant recharging and temperature control. As soon as the PTAB completes its review of the remaining three challenged patents , due within days, the company will return its attention to the infringement lawsuit against Axonics and request that the U.S. District Court in the Central District of California lift the stay and resume proceedings. "Medtronic is pleased with the PTAB's decisions today," said Brett Wall, executive vice president and president of the Neuroscience Portfolio at Medtronic. "We believe competition drives innovation and is good for the industry and for patients. We also believe that protecting our proprietary technology and intellectual property is vital to our business." The PTAB's latest decisions uphold all the claims in Medtronic's U.S. Patent Nos. 8,036,756 and 8,626,314, which protects technology related to its tined leads; and upholds claim 7 in Medtronic's U.S. Patent No. 7,774,069 , which protects technology related to its recharge power control. The PTAB's decision on the '069 patent also found claims 5, 6, 8 and 9 invalid, while claims 1-4 and 10-13 were not challenged by Axonics.

17:27 EDT Herbalife Nutrition cuts FY21 EBITDA view to $860M-$910M from $875M-$935M

17:17 EDT Renewable Energy's renewable diesel plant in Geismar resumes normal operations - Renewable Energy President and CEO, Cynthia Warner, stated: "I am pleased to report that the REG Geismar renewable diesel plant has returned to normal operations following the impact of Hurricane Ida."

17:06 EDT Veoneer says merger pact with Magna remains in full force and effect

16:58 EDT 1-800-Flowers.com CFO sells 50K shares of common stock - In a regulatory filing, 1-800-Flowers.com disclosed that its CFO William Shea sold 50K shares of common stock on September 9th in a total transaction size of $1.6M.

16:36 EDT Akerna to acquire 365 Cannabis in $17M deal - Akerna "announced it has signed an agreement to acquire 365 Cannabis, a cannabis business management software system built on Microsoft's Dynamics 365 Business Central in a $17M deal at 2.1-times last-twelve-months revenue."

16:34 EDT Fox Corp. closes deal to acquire TMZ from WarnerMedia - Fox Corp.'s (FOXA) entertainment division announced that it has closed its acquisition of TMZ from AT&T's (T) WarnerMedia. Fox will now own and operate all of TMZ's linear, digital and experiential assets and said it plans to mobilize TMZ across its station group, free, ad-supported streaming outlet Tubi and other platforms, according to Deadline's recounting of the deal closing announcement. While terms were not disclosed by Fox, Deadline's Dade Hayes said the deal is "believed to be worth in the range of $100M-$125M." Reference Link

16:32 EDT National Health Investors collects 90% of contractual cash due for September - National Health Investors provided a business update regarding its monthly contractual cash collections and average occupancy from its three largest senior housing operators. NHI agreed to defer $1.0 million in rent due for September from Bickford Senior Living. Deferred rents related to Bickford total $3.5 million for the third quarter of 2021 and $13.8 million for 2021. NHI agreed to defer approximately $0.5 million in rent for two other tenants in September which is expected to be repaid with interest. As previously announced, NHI's tenant for the legacy Holiday Retirement portfolio of 18 properties was recently acquired. NHI has yet to receive payment for either August or September rent. NHI continues to hold $8.8 million in Holiday security deposits. In September 2021, NHI sold an acute care hospital in Jackson, KY for $9.0 million in cash consideration which is estimated to result in an impairment charge of approximately $1.5 million. Rental income for this property was approximately $1.8 million for the six months ended June 30, 2021. NHI has collected 80.9% of contractual cash due for September. The remaining balance for the month is comprised of the following: 3.8% in deferrals related to Bickford; 1.8% in deferrals agreed to with two tenants; 8.4% related to the legacy Holiday properties; 4.5% related to amounts expected to be collected; and 0.6% related to lower forecasted revenue from transitioned properties prior to the start of the pandemic. NHI has collected 84.5% of contractual cash due for the third quarter of 2021. The remaining balance is comprised of the following: 4.4% in deferrals related to Bickford; 2.1% in deferrals agreed to with three tenants; 6.7% related to the legacy Holiday properties; 1.7% related to amounts expected to be collected; and 0.6% related to lower forecasted revenue from transitioned properties prior to the start of the pandemic. Please see the Company's Form 10-Q for the quarter ended June 30, 2021, and prior press releases for more information regarding rent concessions.

16:30 EDT Victory Capital reports AUM of $164.9B as of August 31 - Victory Capital Holdings reported assets under management of $164.9B as of August 31, 2021.

16:25 EDT Oracle reports short-term deferred revenues were $10B - Operating cash flow was up 17% to $15.3B during the trailing twelve months.

16:25 EDT Oracle reports Q1 adjusted operating margin 45%

16:23 EDT Proterra CFO Amy Ard to depart, A.J. Cederoth named interim CFO - Proterra announced changes to the executive team. Proterra also announced that CFO Amy Ard will depart the company following a transition period. The company said that Ard's departure is not the result of any disagreement regarding Proterra's financial reporting or accounting. A.J. Cederoth, a public company finance executive with more than 20 years' experience at Navistar International, including serving as CFO, has been appointed interim CFO. Ard will step down from her role as CFO effective September 15, before departing Proterra over the next few months. She will work closely with Cederoth to ensure a transition of responsibilities prior to her official departure from the company. The company has initiated a search, with the support of executive recruiting firm Egon Zehnder, to identify Proterra's next CFO.

16:21 EDT AllianceBernstein reports preliminary AUM $761B as of August 31 - AllianceBernstein announced that preliminary assets under management increased to $761B during August from $748B at the end of July. Market appreciation and firmwide net inflows drove the 2% increase. In the month of August, net inflows to Retail and Institutions were partially offset by modest net outflows from Private Wealth.

16:20 EDT Air Products says Susan Carter to leave board - Air Products announced that Susan Carter will leave the company's Board of Directors effective September 30, following 10 years of dedicated service. Most recently, Carter served as a member of the Air Products Board's Audit and Finance Committee and Management Development and Compensation Committee. Over the past decade, she has contributed her significant experience in financial reporting, information technology, accounting, finance and capital management, investor relations and international operations, underpinned by her prior roles as chief financial officer of several global, publicly held companies.

16:18 EDT Installed Building Products acquires Five Star Building Products, MT Insulation - Installed Building Products announced the acquisition of Five Star Building Products, LLC and Five Star Building Products of Southern Utah, LLC . Five Star primarily installs fiberglass insulation and garage doors to residential and multifamily customers. IBP also announced today the acquisition of MT Insulation, LLC, a Hummelstown, Pennsylvania based installer of insulation and gutters to residential and commercial customers in the greater Harrisburg, Pennsylvania area." The acquisitions add approximately $25M and $4M of annual revenue respectively.

16:18 EDT Vimeo reports monthly YoY growth trends through August up 33%

16:17 EDT Iqvia to partner with NRx Pharmaceuticals on novel COVID treatment - Iqvia (IQV) "announced a transformative collaboration with NRx Pharmaceuticals (NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions. This collaboration will allow NRx to access IQVIA's domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization of ZYESAMI. IQVIA will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs."

16:16 EDT Invesco reports preliminary AUM $1.56T as of August 31 - Invesco reported preliminary month-end assets under management of $1.56T, an increase of 2.2% versus previous month-end. Total net inflows were $13.6B. The firm achieved net long-term inflows of $8.4B this month.

16:13 EDT Benchmark Electronics names Dave Clark as Chief Procurement Officer - Benchmark Electronics announced the expansion of its Global Operations Team with the appointment of Dave Clark as senior vice president, chief procurement officer. Dave will now lead all aspects of Benchmark's global Supply Chain Management organization and will be instrumental in driving operational excellence across the entire purchasing value stream throughout the product lifecycle for our customers. Most recently, Clark served as director, private equity services- supply chain, procurement and manufacturing operations for Alvarez & Marsal.

16:12 EDT Manning & Napier reports preliminary AUM $22.7B as of August 31 - Compared with $22.5B at July 31, and $22.3B at June 30.

16:10 EDT DigitalBridge to partner with ImpactData - The company states: "DigitalBridge announced a partnership with ImpactData, which partners with colleges and universities to build secure colocation data centers that give enterprises better access to their workloads while encouraging digital expansion in underserved communities."

16:09 EDT Oracle CEO calls Q1 results 'excellent' - "Q1 results were excellent as constant currency revenue beat guidance by $100 million with all revenue segments exceeding forecast, and Non-GAAP earnings per share beating guidance by $0.08," said Oracle CEO, Safra Catz. "Oracle's two new cloud businesses, IaaS and SaaS, are now over 25% of our total revenue with an annual run rate of $10 billion. Taken together, IaaS and SaaS are Oracle's fastest growing and highest margin new businesses. As these two cloud businesses continue to grow they will help expand our overall profit margins and push earnings per share higher." "Last week, Cloud Wars published an article entitled 'Oracle Leapfrogs Google in Major Cloud Ranking' summarizing an upcoming Gartner Report that reviews the leading cloud infrastructure companies," said Oracle Chairman and CTO, Larry Ellison. "Please read the article and the Gartner Report for all the essential details. Oracle is delivering some truly innovative infrastructure services. Last quarter, we released the next generation of the world's most popular open source database, MySQL, which now includes the HeatWave in-memory query accelerator, and the AutoPilot management tools. Many customers measured our new MySQL cloud service to be much much faster, less expensive, and easier to use than SnowFlake, Aurora, RedShift and other commonly used cloud databases. In response to requests from some of those customers, we decided to make MySQL HeatWave available on other clouds in addition to the Oracle Cloud."

16:08 EDT Oracle reports Q1 Fusion ERP cloud revenue up 32% - Reports Q1 NetSuite ERP cloud revenue up 28%.

16:07 EDT BRP Group to acquire 'substantially all' assets Jacobson, Goldfarb & Scott - BRP Group has entered into an agreement to acquire substantially all of the assets of Jacobson, Goldfarb & Scott, Inc., including the equity interests of certain of its subsidiaries . Based in Holmdel, New Jersey, JGS is a specialty insurance broker and MGA primarily focused on providing commercial insurance services to middle-market clients across the country. With annual revenues of approximately $43.3M, represents BRP Group's largest announced Partnership in 2021 and fifth "Top 100" Partnership since the beginning of the fourth quarter of 2020. The Partnership, BRP Group's nomenclature for a strategic acquisition, is expected to close on or around October 1, 2021, subject to certain closing conditions.

16:07 EDT Oracle reports Q1 cloud services and license support revenues up 6% to $7.4B

16:06 EDT Oracle reports Q1 Cloud license and on-premise license revenues $813M, down 8%

16:01 EDT Renren names Chris Palmer as CFO, effective September 6 - Renren (RENN) announced that Chris Palmer has been appointed as the company's CFO, effective September 6. Palmer succeeded Lucy Yang, who will continue to serve as CFO of Kaixin Auto Holdings (KXIN). Prior to Joining RenRen, Palmer served as VP Finance at Twist Bioscience, a Global manufacturer of Synthetic DNA.

14:11 EDT Radware jumps 11% after CNBC says company in talks to sell to PE buyer - Shares of Radware are up $3.74, or 11%, to $38.76 following CNBC's report of the takeover talks.

13:12 EDT Zoom building new Whiteboard experience, working on Facebook VR support - Zoom (ZM) said in a blog post that it is building a new persistent whiteboard experience that enables powerful, easy-to-use visual collaboration before, during, and after a virtual meeting. "Zoom Whiteboard will be your powerful virtual hub for real-time and asynchronous collaboration, creating more engaging and efficient meeting experiences," the company said. "Any team, from enterprise to education, can use the Zoom Whiteboard experience to create, annotate, and share ideas from any device whether you're in a Zoom meeting or not. This persistent collaboration using powerful tools on any device will allow your teams to have the creative space to work together, wherever. We plan to offer Zoom Whiteboard in beta later this year." In addition, the company said that it and Facebook (FB) are working together to offer a more immersive product experience, anticipated next year, using virtual reality. "Facebook's Horizon Workrooms is a new VR app that lets people come together in the same VR room for meetings, regardless of physical distance," Zoom said. "This integration will bring Zoom Meetings and Zoom Whiteboard into the VR space using Oculus headsets to enable users to visualize their entire canvas without the need for a large screen." Reference Link

13:11 EDT Zoom building new Whiteboard experience, working on Facebook VR support - Zoom said in a blog post that it is building a new persistent whiteboard experience that enables powerful, easy-to-use visual collaboration before, during, and after a virtual meeting. "Zoom Whiteboard will be your powerful virtual hub for real-time and asynchronous collaboration, creating more engaging and efficient meeting experiences," the company said. "Any team, from enterprise to education, can use the Zoom Whiteboard experience to create, annotate, and share ideas from any device whether you're in a Zoom meeting or not. This persistent collaboration using powerful tools on any device will allow your teams to have the creative space to work together, wherever. We plan to offer Zoom Whiteboard in beta later this year." In addition, the company said that it and Facebook (FB) are working together to offer a more immersive product experience, anticipated next year, using virtual reality. "Facebook's Horizon Workrooms is a new VR app that lets people come together in the same VR room for meetings, regardless of physical distance," Zoom said. "This integration will bring Zoom Meetings and Zoom Whiteboard into the VR space using Oculus headsets to enable users to visualize their entire canvas without the need for a large screen." Reference Link

12:29 EDT Airbnb says New York's 2309-2021 imposes expensive requirements - On New York's proposed legislation Int. 2309-2021, Airbnb said in a statement: "With regards to this legislation, Airbnb agrees with the belief of the sponsors that New Yorkers have the right to share their own space and that short-term rentals are an important element of a growing and recovering tourist economy that democratizes the tourism industry and shares the economic impact across neighborhoods throughout the five boroughs...Fundamentally, 2309 is a registration bill. However, not only does it impose expensive, onerous, and at times redundant requirements on every day New Yorkers seeking to make ends meet, but the legislation fails to provide requirements to the administering agency, OSE, on what types of units in New York City are eligible for a permit, devise a registration process that the average New Yorker can navigate, or ensure good-faith engagement by any agency that has unfairly and arbitrarily targeted homeowners and renters for years. We're also concerned that the current registration requirements in the bill rest the authority to set the registration fees with the Office of Special Enforcement, but set no statutory cap. This is a slippery slope that would open the door to high registration fees that would overburden the very New Yorkers we are seeking to empower to remain in their home." Reference Link

12:03 EDT Litecoin Foundation confirms not in partnership with Walmart - Litecoin Foundation said via Twitter: "The Litecoin Foundation has not entered into a partnership with Walmart."

12:00 EDT Riskified falls -14.2% - Riskified is down -14.2%, or -$4.11 to $24.77.

12:00 EDT Central Puerto rises 14.8% - Central Puerto is up 14.8%, or 40c to $3.10.

12:00 EDT Mayville Engineering rises 17.9% - Mayville Engineering is up 17.9%, or $2.49 to $16.41.

11:46 EDT CN acknowledges TCI announcement of shareholder meeting requisition - CN acknowledges the announcement made by TCI Fund Management Limited that CIFF Capital UK LP and The Children's Investment Master Fund, acting by TCI, as investment manager, that it is requisitioning a meeting of CN's shareholders. "CN has not yet received the formal requisition from TCI. Once CN is in receipt of the requisition, it will review it and comment further in due course," the company stated.

11:32 EDT Alcoa sees Q3 operational tax epxense over $100M based on recent pricing - Sequentially, adjusted EBITDA in the Bauxite segment is expected to be in line with 2Q21. In 3Q21, the Alumina segment is expected to see $10M impact from higher raw materials prices and higher energy costs. Comments from slides being presented at the Credit Suisse Basic Materials Conference.

11:00 EDT Silk Road says Q3 results will be impacted by hospital capacity constraints - Silk Road Medical provided an update regarding the continued impact of Covid-19 on Q3 financial results. "Throughout the quarter, procedure volumes continue to be impacted by increased hospitalizations and hospital capacity constraints due to the COVID-19 Delta variant. Management believes that these constraints may create uncertainty through the second half of the year," the company said in a regulatory filing ahead its presentation at the Morgan Stanley Global Healthcare Conference.

10:37 EDT Kinder Morgan, Neste partner on renewable fuels logistics project in the U.S. - Kinder Morgan (KMI) is partnering with Neste (NTOIY) to create a premier domestic raw material storage and logistics hub in the United States, supporting increased production of renewable diesel, sustainable aviation fuel and renewable feedstock for polymers and chemicals. Upon completion of the project, Kinder Morgan's Harvey, Louisiana facility will serve as the primary hub where Neste will store a variety of raw materials including, for example, the used cooking oil it collects from more than 40,000 restaurants across the United States. As part of the initial, committed phases of the project, Kinder Morgan will modify existing tanks and piping to enable segregated storage for a variety of raw material across 30 tanks. The scope of work also includes the installation of a new boiler for heating tanks and railcars and infrastructure improvements for rail, truck and marine movements. The project, which is supported by a long-term commercial commitment from Neste, is expected to commence operations in the first quarter of 2023. At Neste's option, the facility can be further expanded.

10:26 EDT Walmart spokesperson says no partnership with Litecoin - A Walmart (WMT) spokesperson tells Bloomberg that the company does not have a partnership with Litecoin ($LTC), as claimed earlier in a fake press release distributed by Nasdaq's (NDAQ) Globe Newswire, and the company is trying to learn more about the news release, which the spokesperson said "isn't real."

10:23 EDT Press release on Walmart partnering with Litecoin might be fake, CNBC reports - A press release that was distributed by Globe Newswire, a Nasdaq OMX (NDAQ) company, earlier this morning and claimed to have been distributed by Walmart (WMT) as the source, stated that the company was announcing "a major partnership" with Litecoin ($LTC). However, the veracity of that press release is now being questioned amid reports it may have been fake, according to CNBC's on-air reporting. The press release was available on Globe's distribution platform, but is not posted on Walmart's corporate website.

10:05 EDT Interactive Brokers announces launch of cryptocurrency trading - Interactive Brokers Group announces its launch of cryptocurrency trading, enabling clients to trade and custody Bitcoin, Ethereum, Litecoin and Bitcoin Cash via Paxos Trust Company. Through Paxos, IBKR clients will be able to trade cryptocurrency alongside other asset classes available on the Interactive Brokers platform creating a unified customer experience. While other crypto exchanges and brokers charge fees of 2.00% of trade value or more and add spreads or markups to the price, cryptocurrency trading with Paxos on Interactive Brokers' platform has low commissions of just 0.12% - 0.18% of trade value, depending on monthly volume, with a USD 1.75 minimum per order. Plus, there are no added spreads, markups, or custody fees

10:03 EDT Sarissa Capital boosts Alkermes stake to 8.15% from 7.01% - Alex Denner's Sarissa Capital Management disclosed late Friday an increased stake of 8.15% in Alkermes, which represents 13.145M shares. In a filing on May 27, Sarissa disclosed a stake of 7.01%. The filing with the SEC allows for activism.

10:01 EDT Medtronic announces pilot program with Mpirik - Medtronic announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac arrest, a condition in which the heart suddenly and unexpectedly stops beating. SCA is caused by a disturbance in the heart's electrical system, and can be deadly if not treated by defibrillation within minutes. The Medtronic collaboration with Mpirik also involves Vizient, a health care performance improvement organization that provides data and analytic insights. This pilot program aims to identify patients at higher risk for SCA, and identify them earlier in their care journey. Mpirik's proprietary artificial intelligence platform, Cardiac Intelligence, will screen electronic health records data at five pilot hospitals, including three Vizient member hospitals, to spot patients, regardless of race or gender, who meet prespecified clinical criteria for being at risk of SCA. Mpirik will provide an automated alert through the EHR system for these patients, enabling clinicians to determine appropriate follow-up care. The identification process will continue to protect patient health information, none of which will be shared with Medtronic or Vizient.

10:00 EDT CS Disco falls -9.7% - CS Disco is down -9.7%, or -$6.38 to $59.29.

10:00 EDT Banco Macro rises 15.5% - Banco Macro is up 15.5%, or $2.83 to $21.12.

10:00 EDT Mayville Engineering rises 23.1% - Mayville Engineering is up 23.1%, or $3.22 to $17.14.

09:47 EDT Riskified falls -9.2% - Riskified is down -9.2%, or -$2.67 to $26.21.

09:47 EDT Onion Global falls -10.9% - Onion Global is down -10.9%, or -74c to $6.05.

09:47 EDT Central Puerto rises 13.7% - Central Puerto is up 13.7%, or 37c to $3.07.

09:46 EDT NuVasive says not withdrawing 2021 guidance 'at this time' - NuVasive said today in an investor presentation, "Not withdrawing or updating full-year 2021 guidance at this time; will continue to monitor and assess."

09:36 EDT AB Value files definitive proxy statement for Rocky Mountain Chocolate meeting - AB Value Management LLC, collectively with its affiliates, and the other participants in this solicitation representing approximately 14.63% of the outstanding shares of Rocky Mountain Chocolate Factory, filed their definitive proxy statement with the U.S. Securities and Exchange Commission to solicit proxies for the election of their five, highly-qualified, independent director candidates-Andrew Berger, Mary Kennedy Thompson, Mark Riegel, Sandra Elizabeth Taylor and Rhonda Parish-at the Company's 2021 Annual Meeting of Shareholders. AB Value said, "The Concerned Shareholders of Rocky Mountain believe the Company's proxy materials continue a pattern of false and misleading statements about the Company's actions and engagement with the Concerned Shareholders of Rocky Mountain. Summarized below are a few of the most egregious fictions contained in the Company's filings and how those misrepresentations can be combatted with facts that show the Company is manipulating the truth for its benefit."

09:33 EDT JPMorgan Wealth Management eliminates upfront fee on 529 plans - J.P. Morgan Wealth Management announced that it will offer its advisor-sold 529 plans without the industry standard upfront fee. With this change, more of what the client invests goes towards their education goals. College tuition costs are rising 6.3% every year, according to J.P. Morgan's College Planning Essentials report. 529 plans provide a tax-advantaged way for families to invest for the future costs of higher education. Some also can help cover costs of K-12 tuition, vocational school and registered apprenticeships. There are no income limits on contributions or age restrictions on beneficiaries, unlike other types of accounts often used for education. J.P. Morgan Wealth Management advisors will offer select 529 plans without the sales charge, which for advisor-sold investments can be as high as 5.75%. Other fees and expenses will continue to apply.

09:21 EDT Forge Global to go public in $2B merger with Motive Capital - Forge Global, a global private securities marketplace, announced it has entered into a definitive business combination agreement with Motive Capital Corp (MOTV), a special purpose acquisition company sponsored by affiliates of Motive Partners, a financial technology specialized private equity firm. Forge will become a publicly traded company upon the closing of the transaction, currently expected in the fourth quarter of 2021 or first quarter of 2022. The transaction reflects a $2.0B approximate valuation for the pro forma combined company. The transaction is subject to customary closing conditions, including approval by shareholders of Motive Capital Corp and Forge, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission in connection with the transaction and the approval of the South Dakota Division of Banking for the change in control of Forge's subsidiary trust company. "The Forge marketplace has nearly 400,000 registered users, including over 123,000 accredited investors. Private shares have traded in more than 400 companies since inception, representing over $10 billion in volume across 19,000 transactions with buyers and sellers in 70 countries. Through its custody offering Forge Trust, the company has approximately $14 billion in assets under custody and about $600 million of cash across 1.9 million customers," the company stated. Upon completion of the transaction, the combined company is expected to have a fully diluted equity value on a pro forma basis of approximately $2.0B, assuming redemptions are no greater than $90M by existing Motive Capital Corp shareholders. The transaction is expected to deliver approximately $532.5M of gross proceeds to the combined company prior to the payment of transaction expenses and up to $100 million of cash consideration, including the contribution of up to $414M of cash held in Motive Capital Corp's trust account from its initial public offering in December 2020. The combination is further supported by a $50M commitment under Motive Partners' Forward Purchase Agreement and a $68.5M PIPE at $10 per share supported by ION Group, Temasek and Adit Ventures. Certain Motive Partners' funds will provide up to an additional $90M as a backstop via its Forward Purchase Agreement. Existing Forge shareholders are expected to roll 90% of their equity into the combined company. Concurrent with closing, up to $100M of the transaction proceeds will be paid to certain existing Forge shareholders as cash proceeds for a portion of their existing equity. The transaction has been unanimously approved by the Boards of Directors of both Motive Capital Corp and Forge.

09:17 EDT Diana Shipping announces time charter contract for M/V Amphitrite - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with BG Shipping Co., Limited, Hong Kong, for one of its Post-Panamax dry bulk vessels, the m/v Amphitrite. The gross charter rate is $27,000 per day, minus a 5% commission paid to third parties, for a period until minimum October 15, 2022 up to maximum December 15, 2022. The charter commenced earlier. The "Amphitrite" is a 98,697 dwt Post-Panamax dry bulk vessel built in 2012. The employment of "Amphitrite" is anticipated to generate approximately $10.58 million of gross revenue for the minimum scheduled period of the time charter.

09:16 EDT Kandi Technologies receives final payment from Fengsheng sale - Kandi Technologies (KNDI) announced that it received the final payment from the sale of its 22% equity in Fengsheng Automotive Technologies Group back to Geely (GELYF). According to the Equity Transfer Agreement, Kandi sold back its interest for approximately $47.3M. Kandi received 50% of the amount after the sale was approved by local Zhejiang provincial authorities and the second 50% installment within six months as stipulated in the agreement. Hu Xiaoming, Chairman and Chief Executive Officer of Kandi, commented, "Receipt of this final payment on time adds to our substantial cash position, enabling us to pursue strategic market opportunities as they arise. In addition to the cash infusion, the exit from Fengsheng improves our flexibility to embrace opportunities up and down the supply chain without concerns about competitive conflicts. We are increasingly optimistic about our prospects, given our financial and technological strengths."

09:14 EDT DexCom COO Blackford resigns to pursue other opportunities - DexCom disclosed that on September 8 it received notice from Quentin Blackford of his intention to resign as Chief Operating Officer effective on September 17 in order to pursue another employment opportunities.

09:13 EDT MicroStrategy says purchased about 8,957 bitcoins in Q3-to-date - In a regulatory filing, MicroStrategy announced that during the third quarter of the company's fiscal year to date, or the period between July 1, 2021 and September 12, 2021, the company purchased approximately 8,957 bitcoins for approximately $419.9M in cash, at an average price of approximately $46,875 per bitcoin, inclusive of fees and expenses. As of September 12, 2021, the company held approximately 114,042 bitcoins that were acquired at an aggregate purchase price of approximately $3.16B and an average purchase price of approximately $27,713 per bitcoin, inclusive of fees and expenses. As previously disclosed, on June 14, 2021, the company entered into an Open Market Sale Agreement with Jefferies as agent, pursuant to which the company may issue and sell shares of its class A common stock, having an aggregate offering price of up to $1.0B from time to time through Jefferies. On September 13, 2021, the company also announced that during the third quarter of the company's fiscal year to date, or the period between July 1, 2021 and September 12, 2021, the company had issued and sold an aggregate of 555,179 shares under the sale agreement, at an average gross price per share of approximately $727.64, for aggregate net proceeds to the company, less sales commissions and expenses, of approximately $399.9M.

09:13 EDT Chevron, Enterprise explore carbon storage business opportunities - Chevron (CVX), through its Chevron New Energies division, and a subsidiary of Enterprise Products Partners (EPD) announced a framework to study and evaluate opportunities for carbon dioxide, CO2, capture, utilization, and storage CCUS from their respective business operations in the U.S. Midcontinent and Gulf Coast. The companies expect the initial phase of the study in which they will evaluate specific business opportunities to last about six months. "This joint effort has the potential to advance our ongoing work to grow our lower carbon businesses with commercial scale using the industry expertise both companies bring to the project," said Jeff Gustavson, president of Chevron New Energies. "International climate change scientists working with the United Nations have identified carbon capture as a critical technology needed to help the global energy system transition to a lower carbon future." The companies have successfully worked together on prior business opportunities and believe they bring complementary capabilities to successfully pursue CCUS. Projects resulting from the evaluation would seek to combine Enterprise's extensive midstream pipeline and storage network with Chevron's sub-surface expertise to create opportunities to capture, aggregate, transport and sequester carbon dioxide in support of the evolving energy landscape.

09:12 EDT Celldex initiates CDX-0159 subcutaneous formulation study - Celldex Therapeutics announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. The Company intends to utilize the subcutaneous formulation of CDX-0159 in its Phase 2 program in chronic urticarias, planned for initiation in the first half of 2022. Celldex is currently studying an intravenous formulation of CDX-0159 in Phase 1 studies in chronic spontaneous and chronic inducible urticarias and will initiate a third intravenous study in prurigo nodularis later this year. The randomized, double-blind, placebo-controlled Phase 1 study will evaluate single ascending doses of CDX-0159 administered subcutaneously in healthy volunteers. Thirty two subjects will be enrolled across four dosing cohorts with 8 subjects in each cohort. Subjects will be followed for 12-weeks after dosing. The primary endpoints of the study are safety and tolerability; secondary endpoints include pharmacokinetics, pharmacodynamics, and immunogenicity.

09:10 EDT Fortinet, Linksys joint venture to deliver secure enterprise solution for remote - Fortinet announced a new joint solution to enable enterprise organizations to support and secure work-from-home networks. Linksys HomeWRK for Business Secured by Fortinet is an enterprise solution to deliver secure network connectivity for both corporate and personal needs in one easy-to-setup unit optimized for business applications and collaboration tools, including Zoom. The announcement serves as another proof point of both companies' long-term commitment to delivering enterprise-grade performance and security for the hybrid era, and follows earlier news of Fortinet's investment in Linksys and the launch of Linksys HomeWRK for Education Secured by Fortinet to bring reliable connectivity and security to students at home. To enable enterprise IT teams of all sizes to ensure enterprise-grade security and high-performance connectivity for remote and hybrid workers at home, Fortinet and Linksys are launching Linksys HomeWRK for Business Secured by Fortinet. This offering builds on Fortinet's commitment to build a safer Internet by protecting people, devices, and data everywhere, and delivers the following key benefits for enterprise organizations: Fast, Reliable, and Secure Wi-Fi Mesh Connectivity; Optimized for Zoom to Boost Team Collaboration; Enterprise-grade Security from Fortinet; Zero-touch Provisioning Simplifies Installation; and etc. "Our goal was two-fold. First, make it very simple for anyone to set up a fast and reliable home Wi-Fi network. Second, provide enterprise IT with the ability to secure and manage the business aspects of that work-from-home Wi-Fi network just as they do with any other device attached to the network. The Linksys and Fortinet joint venture is not just a simple OEM agreement of two distinct parties, it's the start of a completely new market," said John Maddison, EVP of products and CMO at Fortinet.

09:09 EDT AngloGold Ashanti to acquire Corvus for C$4.10 per share in cash - AngloGold Ashanti Limited (AU) and Corvus Gold Inc. (KOR) are pleased to announce that they have entered into a definitive arrangement agreement pursuant to which AngloGold Ashanti has agreed to acquire the remaining 80.5% of common shares of Corvus not already owned by AngloGold Ashanti at a price of C$4.10 per common share in cash. The total Transaction cost to AngloGold Ashanti is estimated to be approximately US$370 million. The Transaction implies a total equity value for all Corvus common shares and outstanding options to acquire common shares of approximately C$570 million. The Offer Price represents a premium of approximately 26% to the closing price of Corvus common shares on the Toronto Stock Exchange on 12 July 2021, the day prior to the announcement that AngloGold Ashanti submitted a non-binding proposal to Corvus, and a premium of approximately 59% to the closing price of Corvus common shares on the TSX on 5 May 2021, the day prior to the announcement of the loan agreement and exclusivity. The combination of Corvus and AngloGold Ashanti's Nevada assets further consolidates one of the largest new gold districts in Nevada and provides the opportunity for AngloGold Ashanti to establish, in the medium and longer term, a meaningful, low-cost production base in a premier mining jurisdiction. Consolidation of the Beatty District has the potential for significant synergies due to economies of scale and integrated infrastructure, including processing facilities at an attractive capital intensity. The combined Beatty District asset base allows for streamlined engagement with federal, state and local stakeholders to advance and achieve shared sustainability goals and other district benefits, such as opportunities to design projects incorporating renewable energy, as well as develop conservation and other local projects in conjunction with the Beatty community. AngloGold Ashanti's conceptual development plan for the district envisions North Bullfrog being developed first, with production in the next three to four years, followed by Silicon, Merli and Mother Lode. Targets will be considered with strict reference to AngloGold Ashanti's capital allocation framework. Further details on AngloGold Ashanti's integrated development plan for the Beatty District will be communicated during 2022. The Transaction will be implemented by way of a statutory plan of arrangement under the Business Corporations Act. The Transaction will be subject to the approval of: 66 2/3% of the votes cast by the holders of Corvus' common shares, including votes attached to common shares held by AngloGold Ashanti, present in person or represented by proxy at the special meeting relating to the Transaction; and the Shareholders and the holders of options, voting together as a single class, present in person or represented by proxy at the Special Meeting; and a simple majority of the votes cast by the Shareholders present in person or represented by proxy at the Special Meeting, excluding votes attached to common shares held by AngloGold Ashanti and any other person as required to be excluded under section 8.1(2) of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. In addition to securityholder approval, the Transaction is subject to the receipt of court approval and other customary closing conditions for transactions of this nature. The definitive arrangement agreement includes customary deal-protection provisions. Corvus has agreed not to solicit or initiate any discussion regarding any other business combination, subject to customary "fiduciary out" rights. Corvus has also granted AngloGold Ashanti a right to match any superior proposal and will pay a termination fee of C$19 million to AngloGold Ashanti under certain circumstances, including if the definitive arrangement agreement is terminated in connection with Corvus pursuing a superior proposal. Sprott Funds Trust, along with the directors and officers of Corvus, holding common shares and options reflecting in aggregate, approximately 34.7% of Corvus' issued and outstanding common shares (on a fully diluted basis and excluding shares held by AngloGold Ashanti), have entered into voting support agreements with AngloGold Ashanti, pursuant to which they have agreed, among other things, to vote their Corvus securities in favour of the Transaction. Together with the shares already owned or held by AngloGold Ashanti, this represents approximately 46.3% of Corvus' issued and outstanding shares. The Transaction is expected to close in Q1 2022. The Transaction will be funded from AngloGold Ashanti Holdings plc's current cash balance. No shareholder vote will be required by AngloGold Ashanti shareholders.

09:07 EDT Srax to issue one-time special dividend on September 20 - Srax announced they will be issuing a one-time special dividend to shareholders of record on September 20. Srax will be issuing non-tradable preferred shares to shareholders of record on September 20. The preferred shares will hold approximately $6.5M worth of Sequire clients stock, and as the shares are sold, the proceeds will be distributed to the preferred shareholders periodically.

09:05 EDT AbCellera acquires biotechnology firm TetraGenetics in all cash transaction - AbCellera announced it has acquired TetraGenetics , a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial milestone payments related to successfully developed therapeutics. TetraGenetics has leading technology and expertise in the expression and purification of ion channels, G protein-coupled receptors, GPCR, and other transmembrane proteins, which are implicated in many human diseases, including pain and autoimmune disorders. High-value transmembrane proteins have proven extremely difficult to produce, making the generation of antibodies against them even more challenging. TetraGenetics has established a protein expression platform that addresses these production challenges and is uniquely able to generate highly pure, complex transmembrane proteins in quantities large enough to support antibody discovery. Integrating TetraGenetics' capabilities into AbCellera's technology stack provides an optimized protein source for AbCellera's antibody discovery. Together, these technologies have the potential to unlock the discovery of antibodies against these validated and sought-after drug targets.

09:05 EDT Luokung Technology: eMapGo to provide technical services for Heilongjiang Mobile - Luokung Technology announced that its operating affiliate, eMapGo Technology Co., has signed an agreement to be the technical service provider for the management of market and service information for China Mobile Group Heilongjiang Co., Ltd., the Heilongjiang division for China Mobile, the leading telecommunications provider in mainland China. This agreement is in effect through December 31, 2022.

09:03 EDT C3.ai awarded Missile Defense Agency production OT agreement - The Missile Defense Agency, or MDA, awarded a Production Other Transaction, or OT. Agreement to C3 AI to aid in enterprise AI development initiatives across the agency. C3 AI was previously competitively selected for award of a Prototype OT to demonstrate the C3 AI Suite's ability to develop a Generative Modeling Application for hypersonic missile trajectories. The Production OT is a standalone follow-on to a Defense Innovation Unit Prototype OT. It builds upon the success of previous prototype efforts centered on applying AI to digital engineering initiatives such as the design of experiments, scenario simulation, and generative modeling.

09:03 EDT 3M down 1% after discussing inflation, chip shortage impacts at conference - Shares of 3M are down 1% to $182.70 in pre-market trading as the company's CFO Monish Patolawala presents at Morgan Stanley's Laguna Conference and discusses the impacts of cost inflation, pricing and the ongoing industry-wide semiconductor shortage.

09:03 EDT LMP Automotive acquisition agreement to purchase 5 import dealerships in Texas - LMP Automotive announced its entry into a definitive acquisition agreements to purchase five import dealerships in Texas, including the associated real estate, generating approximately $592M in annualized revenue and $35M in adjusted EBITDA. The deal is: expected to close in the fourth quarter of this year; aggregate purchase price of approximately $62.5M for goodwill expected to be funded through a combination of cash on LMP's balance sheet, up to $6.25M in common stock and debt financing; aggregate real estate price of approximately $55M; and expected to add approximately $35M in adjusted EBITDA or $2.95 per share in 2022. Richard Aldahan, LMP's Chief Operating Officer, stated, "This acquisition will further expand our management team and footprint in the central region. This will be the final acquisition we expect to close this year, which completes our Stage 2 acquisition plan. All future perspective acquisitions we expect to consolidate in our Stage 3 plan for closings in 2022."

08:51 EDT 3M CFO says 'inflation is higher than we even thought' in Q3 - While presenting at Morgan Stanley's Laguna Conference, 3M CFO Monish Patolawala stated in part, according to a transcript of the event: "As you've seen our results for the first half, we had a pretty good start to the first half. The team delivered strong organic growth, improved margins. We have also had good cash flow... On the long term, when I look at the business, we still feel very bullish about the trends that exist that have come through the pandemic... And so we are continuing to invest despite all the uncertainty in our growth, productivity and sustainability goals. And then if we come back to the short term [...] during our earnings update, we had talked about some of the uncertainties that we are seeing in the world. And I think it's starting to play itself out... All of us are experiencing the semiconductor shortages that are not just linked, I would say, to automotive and electronics, but you're starting to see it impact a lot of industries. The outbreak of the Delta variant continues to impact the world. As well as Hurricane Ida has also put more stress now on already stressed supply chains, causing a lot of inflation as well as material availability across -- issues across the globe. So if I take it one notch lower, I'll just start with auto, the semiconductor shortage impacting both auto, electronics. Auto, you're seeing a lot of OEMs are shutting down manufacturing because of the lack of semiconductor chips. Auto, which was expected to be down minus 3% for the second half of the year, auto builds, is now going to be down 6% for the second half. Electronics is getting impacted. So consumer electronics, TVs, are all getting impacted by the chip shortage. But also TVs, we are seeing that factories are being shut down because of the Delta variant in many parts of the world. So that's going to put more pressure on basically what was already going to be a negative year-over-year comp and it's going to make it worse. When I move over to health care, you're seeing uneven recovery in health care. So in certain places, you're seeing procedures remaining as they were. In certain cases, you are seeing procedures starting to come down. We see right now that North American elective procedures will be approximately 90% of pre-pandemic levels. Going into the third quarter, we have thought we would be closer to the 90% to 95%, but we're going to be at the lower end, and even lower depending on where it goes... Moving over to raw materials. Again, I think the inflation is unprecedented. We are seeing inflation in the same areas I talked about earlier, jobs, raw material, labor and logistics. Raw materials, again, you go down to polypropylene, you talk about resins, that inflation remains. We saw it dip a little bit, it's back up again. And then logistics cost, we read about it, you read about it, you all have written about it, where you're seeing port congestion, you're seeing a lot of pressure on logistics costs. And so when we look at all the inflation and all these metrics that we look at, we had talked about a 65c to 80c headwind for the year. We see ourselves currently at the higher end of that range as well as we haven't yet factored in the impact of Hurricane Ida because I think people are still just coming off Hurricane Ida, we'll have to figure out what material availability is and we'll see where that goes. And our plan is to update you during our earnings conference in October. Price, we are gaining price. So we have been able to gain price versus the first half, pretty much to what we expected, so price is up. Unfortunately, inflation is higher than we even thought in the third quarter. So despite taking price up, getting the positive, we are seeing inflation outstrip price. So when we come in at earnings, we had told you 50 to 100 basis points of pressure between the net of price raw. Currently, we look at it somewhere between 100 to 150 basis points of pressure in Q3... But again, it's 2 months in. We got a month to go, September is a big month for us, the team's all focused on making sure we are delivering for our customers, reducing the cost where we can, increasing price. But at the same time, we are bullish about the long term. So we're going to continue to invest in growth, productivity and sustainability and we'll keep fighting this."

08:49 EDT TOMI Environmental Solutions launches Amazon store for SteraMist products - TOMI Environmental Solutions launched a new Amazon store for select SteraMist products, including the recently launched SteraPak, in the USA. TOMI has partnered with Orca Pacific to build and optimize TOMI's Amazon store and to execute advertising initiatives for TOMI's products. In partnering with Orca and launching an Amazon store, TOMI enables businesses and consumers to easily gain access to its leading hospital-healthcare and broad-spectrum disinfectant products.

08:48 EDT DiaMedica starts trial of DM199 for the treatment of acute ischemic stroke - DiaMedica Therapeutics announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke, AIS. The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States. Patients enrolled in the study will be treated with either DM199 or placebo within 24 hours of the onset of AIS symptoms. The study excludes patients treated with tissue plasminogen activator tPA and those with large vessel occlusions. The study population is representative of the 80% of AIS patients who do not have treatment options today, primarily due to the short treatment window of 4.5 hours required for administration of tPA. The ReMEDy2 trial has two primary endpoints and is powered for success with either endpoint: 1. recovery from stroke as measured by the well-established modified Rankin Scale, mRS, at day 90, and 2 the rate of ischemic stroke recurrence at day 30. Recurrent strokes represent 25% of all ischemic strokes, often occur in the first few weeks after an initial stroke and are typically more disabling, costly, and fatal than initial strokes. Secondary endpoints for the study will evaluate participant deaths, mRS shift which shows the treatment effect on participants across the full spectrum of stroke severity and additional standard stroke scores. "Our investigators are enthusiastic to study a promising new therapy for their patients with the flexibility of a 24-hour treatment window, particularly given the challenges in emergency medicine today," said Rick Pauls, DiaMedica's Chief Executive Officer. "By either or both improving overall recovery and reducing the risk of a recurrent stroke, DM199 could be the first new therapeutic in 25 years that could meaningfully change outcomes for stroke patients. Stroke represents a significant, unmet medical need for approximately 700,000 patients annually in the U.S. and millions more globally."

08:47 EDT Logiq receives Indonesian Government approval offer for micro-lending services - Logiq has received approval of an annual lending rate from the Indonesian Government to provide micro-lending services to the more than 50M members of Badan Perlayanan Jaminan Sosial Ketenagakerjaan, BPJSTK. BPJSTK manages the pensions and health benefits for these members in Indonesia. The lending rate approval follows Logiq's earlier announced launch of a program to provide mobile fintech services in an exclusive strategic alliance with the country's social security program provider, Koperasi Mona Santoso Berjaya. The rate approval allows Logiq to begin the initial rollout of its new mobile fintech offering to the 5M contract and delivery drivers of Garda Digital Indonesia, a membership organization overseen by BPJSTK, as well as 6,000 government body employees. Under their exclusive alliance, Logiq and KMSB are developing a jointly owned and operated mobile fintech platform designed to deliver these mobile financial services throughout Indonesia. Logiq, through its Indonesian operations, is providing the platform design and technology, management, ongoing hosting and technical support. KMSB is providing the professional and financial institutional relationships that will drive the micro-lending program. The partners are also working to launch a new marketing and advertising campaign designed to encourage adoption and regular use of the mobile fintech offerings. Through the new fintech platform, KMSB will provide micro-lending services to government, state-owned enterprises and member organizations registered with BPJSTK. As part of managing the pensions and health benefits for contract and delivery driver members, BPJSTK serves as the social security agency that administers retirement and pension plans on behalf of Indonesian government entities and about 600,000 small- and medium-sized businesses, with the combined total of 50 million individual members. The mobile fintech platform is planned to be eventually introduced to all BPJSTK members, as well as to affiliated organizations, such as Mentalku, which supports the motor vehicle license administration, and Sehatku, a medical clinic organization network.

08:47 EDT mdf Commerce extends eprocurement footprint in Canada - mdf commerce announced the onboarding of eight new agencies and municipalities to the Government of Newfoundland and Labrador's merx electronic procurement solution, strengthening its eprocurement leadership position in North America. First launched in November 2020, the quick and successful onboarding of additional agencies reinforces mdf commerce as a trusted partner for province-wide eprocurement solutions, which will soon be enhanced with the Periscope Holdings offering. Since the onboarding of the GNL, more than 3,000 supplier organizations have accessed close to 900 solicitations with more than 1,000 bids submitted via the electronic submission option. The end-to-end eprocurement platform offered by mdf commerce effectively manages and is designed to ensure that all bid opportunities from these agencies are competitive, fair and transparent while complying with all required public policies and legislation. Vendors benefit from self-serve profile management capabilities, timely notifications and a start-to-finish online submission. Virtual introductory sessions are available on-demand for those new to the system. The latest agencies that joined are: NL Provincial Health Shared Services Supply Chain, the supply chain lead for all commodities being sourced and undergoing contract on behalf of all Regional Health Authorities and the Newfoundland and Labrador Centre for Health Information. WorkplaceNL, chief administrator of an employer-funded, no-fault workers' compensation system. The College of the North Atlantic, one of the largest post-secondary educational and skills training systems in Atlantic Canada with 17 campuses plus partner universities and technical colleges in China and Qatar. Memorial University of Newfoundland, one of the top 20 research universities in Canada, representing 30 research centers, five campuses and more than 19,000 students. MUN, already a long-time mdf commerce customer, expanded their use of e-solicitation capabilities with the added efficiency of e-bidding. New municipalities include: City of Corner Brook; Town of Logy Bay-Middle Cove-Outer Cove; Town of Point Leamington; Town of Carbonear.

08:44 EDT AFC Gamma expands existing senior secured credit facility with Devi Holdings - AFC Gamma announced it has expanded its senior credit facility by $30 million to Devi Holdings Inc., doing business as Nature's Medicines, a multi-state operator headquartered in Phoenix, Arizona. The credit facility is designed to provide Nature's Medicines with additional capital to complete strategic acquisitions and further expand its existing business operations. AFC Gamma has committed an additional $20 million under the expansion to the credit facility, and now holds $62.5 million in total of the expanded credit facility, and $10 million of the expansion was syndicated to an affiliate. The loan is secured by a first-lien mortgage on all of Nature's Medicines owned real-estate and other commercial-security interests. AFC Management, LLC served as Lead Agent for the transaction.

08:44 EDT Legend Biotech starts U.S. trial to evaluate LB1901, CAR-T, therapy for CTCL - Legend Biotech has announced the start of a Phase 1 clinical trial in the United States for LB1901, an investigational autologous CD4-targeted chimeric antigen receptor T-cell, CAR-T, therapy for the treatment of adults with relapsed or refractory peripheral T-cell lymphoma PTCL or cutaneous T-cell lymphoma, CTCL. LB1901 targets CD4, a surface membrane glycoprotein uniformly expressed in most TCL subtypes. The trial follows the U.S. Food and Drug Administration clearance of the Investigational New Drug application submitted by Legend Biotech. The Phase 1 trial is being led by Dr. Swaminathan P. Iyer, Professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, and is an open label, multi-center and multicohort clinical study in patients with relapsed or refractory PTCL or CTCL . Recruitment in the trial has begun in the U.S. "We are excited by the promise of LB1901, and we look forward to further evaluating the safety and tolerability of LB1901. Determining the optimal dose for subsequent evaluation is one of the key objectives of this trial," said Dr. Lida Pacaud, Vice President of Clinical Development at Legend Biotech. "The number of patients who relapse or are refractory to current TCL treatments is significant, and this trial will provide important information about the potential of CAR-T therapy to treat this disease."

08:41 EDT Exela Technologies expands PCH Global Cloud Solution with insurer - Exela Technologies announced an expansion with one of the largest insurance carriers in the country. This expansion highlights the Company's ability to rapidly implement PCH Global for claims submitted by providers, in this case servicing members that are from low income and disadvantaged communities across America. Exela continues to invest in expanding PCH Global's capabilities to provide a cloud hosted solution with one of the best edit resolutions for healthcare claims. This extension of deployment marks another milestone in the value proposition of the PCH Global platform to digitally connect members, providers and insurance companies for clean claims, payment transparency and digital appeals. Additionally, this expansion further augments an existing $180 million Total Contract Value relationship.

08:40 EDT Alto Ingredients to install Harvesting Technology's CoPromax - Alto Ingredients will install Harvesting Technology's patented CoPromax protein system at Alto Ingredients' Magic Valley, Idaho facility. "We are upgrading our Idaho facility with the installation of the CoPromax protein system as an integral part of our strategy to expand and diversify our essential ingredient product offerings. This system will produce new, concentrated protein feed and food ingredients," said CEO Mike Kandris. "Upon completion, the CoPromax system will produce over 33,000 tons annually of feed with a protein content greater than 50%. It will also provide the added benefit of increasing corn oil yields by 50%, or almost 9 million pounds annually. We conservatively expect the combination will result in an annual increase of $7.8 million in gross profit and approximately $9.0 million of EBITDA. This represents approximately 15 cents per gallon and a payback of less than three years. We expect the growing demand for protein in the cattle, poultry, pork, and aquaculture industries to provide market support for our enhanced, high value protein product. We plan to resume operations at our Magic Valley facility, with an annual production capacity of 60 million gallons, and to commission the new system in the first half of 2022. With the successful completion of this installation, we expect to roll out the CoPromax systems, with similar economics at our other three dry mills totaling 190 million gallons of annual capacity as we build on our abilities to produce low carbon alcohols and essential ingredients into 2023 and beyond."

08:39 EDT CACI wins $36M task order to advance USTRANSCOM's DPS - CACI International announced that it won a single-award task order to continue to provide enterprise technology support advancing the U.S. Transportation Command's, USTRANSCOM, Defense Personal Property System, DPS. Awarded under the Defense Information Systems Agency's Encore III contract vehicle, this task order is worth more than $36M and further expands CACI's work in digital modernization solutions. USTRANSCOM provides global air, land, and sea transportation for the Department of Defense DOD. Its services and information systems deliver synchronized transportation, distribution, and sustainment, enabling projection and maintenance of national power with efficiency and accuracy. DPS is USTRANSCOM's web-based system for managing personal property shipments for DOD employees and all service members, representing approximately 15% of all domestic and international moves. John Mengucci, CACI President and Chief Executive Officer, said, "Military service members and DOD personnel complete about 400,000 personal shipments a year. Easing this process with technology helps DPS ensure personal property are accounted for and transported safely. Using Agile-at-Scale methodologies and data analytics, CACI has deployed innovative software solutions to reduce technical debt, enhance productivity, improve usability, and maintain critical records at optimal cost and efficiency."

08:38 EDT Scynexis announce Hansoh Pharma's application to NMPA in China for Phase 3 study - SCYNEXIS announced that Hansoh Pharmaceutical Group has filed an investigational new drug application with the National Medical Products Administration, NMPA, of the People's Republic of China for a Phase 3 study evaluating the efficacy and safety of ibrexafungerp for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. "This clinical trial application is a critical first step as Hansoh works to develop and bring this groundbreaking antifungal treatment to potentially millions of patients in China," said Marco Taglietti, M.D., President and CEO of SCYNEXIS. "We believe Hansoh Pharma has exactly the right capabilities and expertise to successfully develop and commercialize ibrexafungerp in China, and we are thrilled to see the team achieve this important milestone."

08:37 EDT Limestone Boat Company ships two test models to Vision Marine Technologies - The Limestone Boat Company Limited announced that its first two Test Boats are en route to Vision Marine Technologies or fitting of their innovative EV Outboard engines.

08:36 EDT Ecolab sees short-term impact on EPS due to Hurricane Ida - Ecolab commented on the effects of Hurricane Ida, saying it expects the company will see a short-term impact on EPS due to higher delivered product costs, temporary customer closures as well as temporary disruption at one of its major production facilities. The company does not expect a material impact on its strong top line growth and sees this as a one-time event which should not have significant impact beyond year-end, though these supply chain issues are likely to partially offset continued strong fundamental sequential and year-on-year earnings improvement in its business through the second half of 2021. Christophe Beck, Ecolab's president and chief executive officer, said, "We continue to expect strong year-on-year growth as well as further sequential sales and earnings per share improvements in 2021 led by a very successful Institutional recovery and continued improvements in the Industrial segment, as we remain focused on driving new business wins, product and service innovation, accelerating pricing, and investments in new hygiene and digital technologies. Further, we expect the strong underlying momentum to continue into 2022 as we build on these core business drivers. However, Hurricane Ida directly hit a key area for U.S. chemical production and is having a uniquely outsized impact on a number of companies, including us. We view this as another temporary impact to 2021 and remain confident in our fundamental business outlook as we continue to see improving year-over-year and sequential trends in our sales and earnings. We are undertaking the right actions to ensure our raw material supply, implement appropriate pricing for our products to reflect the higher input costs and to drive cost savings. While we are still assessing the situation and our corrective actions, we currently believe that the impact from Hurricane Ida will be close to the estimated $0.15 negative impact from the Texas freeze, with a significant impact in the third quarter. Our fundamental business progress remains solid with expected 2021 adjusted diluted earnings per share showing strong double-digit growth over 2020, and we expect the business momentum to continue into 2022."

08:35 EDT Valvoline, Cummins renew longstanding marketing, technology partnership - Valvoline (VVV) and Cummins (CMI) announced a five-year renewal of their longstanding marketing and technology partnership agreement. Under this renewal, Cummins will endorse and recommend Valvoline's Premium Blue engine oil for its heavy-duty diesel engines and generators and will sell Valvoline product through its multiple channels worldwide. Additionally, Cummins' plants across the globe will use Valvoline-supplied lubricants and oils in day-to-day operations.

08:35 EDT Argentine ADRs higher in pre-market following Sunday primary elections results - ADRs of some of the Argentine companies are moving sharply higher in pre-market trading after the results of primary legislative elections over the weekend. According to Reuters, the conservative opposition party fared well against the ruling Peronists in congressional primary, with a five percentage point lead in the key province of Buenos Aires. If repeated in the November 14th elections, the government may lose its majority in the Senate, the report states. Some of the larger ADRs rallying on the results are Grupo Financiero Galicia (GGAL), up 15.1%, YPF Sociedad Anonima (YPF), up 9.1%, and Grupo Supervielle (SUPV) up 14.2%. Reference Link

08:34 EDT ImmunityBio announces updated data from QUILT 3.032 study - ImmunityBio announced updated data from an ongoing bladder cancer trial showing sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ, or CIS, bladder cancer. Of the 81 patients in the QUILT 3.032 study, 58 patients had a complete response at any time to intravesical BCG plus N-803 with median duration of CR of 19.9 months. The data also showed a 59% probability that responding patients would maintain a complete response for more than 12 months, based on Kaplan-Meier analysis. For the patients who had a CR within the first three months, the CR rate was 77%, with a 61% probability of remaining disease free at 18 months with the median duration of complete response having not yet been reached in that group. 85% of patients in the cohort avoided a cystectomy with a median duration of follow-up of 20.4 months. Of note, the therapy was extremely well tolerated with 0% treatment-related SAEs, 0% immune-related AEs and 0% grade 4 or 5 treatment-related AEs. In contrast, the currently approved checkpoint therapy for this indication is associated with an incidence of 21% immune-related adverse events.

08:33 EDT Color Star Technology plans to establish international business unit in Dubai - Color Star Technology officially announces plans to establish an international business unit in Dubai as part of its strategy to deepen high-tech efforts in capturing metaverse opportunities. While using virtual reality and augmented reality technologies, the company will continue to develop smart technologies to enhance the Color Star virtual universe.

08:32 EDT Ascot Resources announces retirement of director Robert Evans - Ascot Resources announces that Robert Evans has decided to retire from the board after 32 years of service. Bob was one of the early founders of Ascot and was CFO of the Company from 1989 to 2017 as well as serving on the board. Ascot is pleased to announce the appointment of Ms. Indi Gopinathan to the board. Ms. Gopinathan brings 25 years of experience in the mining industry and capital markets to Ascot. She is currently VP, Investor Relations and Corporate Communications with IAMGOLD.

08:31 EDT iRhythm names Quentin Blackford as President, Chief Executive Officer - iRhythm Technologies announced that Quentin Blackford has been appointed President and Chief Executive Officer of iRhythm and a member of the Board of Directors, effective October 4, 2021. Blackford has more than 20 years of experience scaling premier innovative medical device and digital health companies, including most recently as Chief Operating Officer of Dexcom. Douglas Devine will continue to serve as the Interim Chief Executive Officer until Blackford joins the company on October 4th, 2021.

08:29 EDT Super League Gaming, PRG form production partnership - Production Resource Group and Super League Gaming announced the formation of a partnership to provide a full spectrum of event support to the esports community. "The esports ecosystem is extremely broad and varied, and decidedly global. Together, Super League and PRG can leverage our diverse strengths and networks to push past current boundaries of the esports event fan experience, elevating all touchpoints from gameplay to sponsorship activations to live music to digital-to-physical engagement," said Matt Edelman, Chief Commercial Officer, Super League. "With PRG's global network of locations and resources, Super League can now activate anywhere at scale." Super League, which is building a global brand at the intersection of gaming, experiences, and entertainment, has expansive capabilities through its Virtualis Studios division to support productions ranging from branded content to live fan-engagement sports programming to dynamic esports tournaments. Within this strategic partnership, PRG will bring its 360 degrees production services, including camera, virtual production, audio, broadcasting, and content team and operations to complement Super League's deep experience running tournaments and producing premium esports broadcasts and accompanying shareable digital content.

08:27 EDT TCI Funds nominates four to Canadian National board, identifies potential CEO - Long-term shareholders CIFF Capital UK LP and The Children's Investment Master Fund, acting by their investment manager TCI Fund Management Limited, announce they intend to requisition a timely special meeting of Canadian National Railway Company shareholders shortly for the purpose of refreshing the current Board of Directors by adding four nominees who will provide the deep railroad operational experience the current Board lacks. TCI's four independent and highly skilled nominees are Gilbert Lamphere, Allison Landry, Rob Knight, and Paul Miller. Chris Hohn, TCI Founder and Managing Partner stated in part, "History has shown that with the right leadership railroads can be improved quickly. TCI's independent and highly skilled nominees, if elected, will help lead and guide the selection of a new CEO. TCI has identified Jim Vena as the outstanding candidate for the position. Mr. Vena has a proven track record as an exceptional operator. His time at CN, where he was a high-performing and well-respected COO, demonstrates he knows how to run a railroad successfully. During his 40 years at CN, Mr. Vena ran all three geographic regions of the network, so he knows the network intimately and is uniquely qualified to be CEO. More recently, Mr. Vena was the COO at Union Pacific, where he drove a remarkable improvement in the company's operations, service, efficiency and profitability, resulting in a 650bps improvement in the operating ratio in two and a half years. Mr. Vena has committed to accepting the role of CEO if offered the position in a suitably expedient manner."

08:26 EDT Proxy advisory firms recommend Tremont Mortgage Trust merger with RMR Mortgage - Tremont Mortgage Trust (TRMT) announced that, on September 10, three proxy advisory firms that advise institutional investors, Institutional Shareholder Services Inc., or ISS, Glass Lewis & Co., LLC, or Glass Lewis, and Egan-Jones Proxy Services, or Egan-Jones, have all recommended that shareholders vote "FOR" the previously-announced merger of TRMT with and into RMR Mortgage Trust (RMRM) at the special meeting of TRMT shareholders to be held on September 17 at 11:00 a.m. Eastern Time. In recommending that TRMT shareholders vote "FOR" the merger, the proxy advisory firms endorsed the strategic, corporate governance and financial merits of the transaction. In separate reports, ISS, Glass Lewis and Egan-Jones also recommended that RMRM shareholders vote "FOR" the issuance of RMRM common shares in the merger.

08:25 EDT Gold Standard Ventures provides Dark Star exploration update - Gold Standard Ventures announced drill results from 20 reverse circulation drill holes at the Dark Star gold deposit. Key Highlights: Drill holes DR21-14 and DR21-15 were completed at Dark Star North to support conversion of certain Inferred resources to Measured and Indicated resources for inclusion in the mine plan. Drill hole DR21-15 intersected an interval of 41.2 meters of 3.06 g Au/t sulphide mineralization directly below the oxide pit boundary. Development Highlights: Drill holes DR21-11, DR21-12, and DR21-17 through DR21-20 were completed at Dark Star Main as in-fill drill holes and intersected ore grade mineralization similar to holes previously drilled at Dark Star Main and indicate that the ore body is still open to the south. Drill holes DR21-01 through DR21-09 were completed on a zone of gravels east of the Dark Star Main deposit. The gold grades intersected represent an eroded portion of the Dark Star Main deposit and are currently being evaluated for utilization / suitability as over-liner on the proposed heap leach pad.

08:22 EDT Kinnate Biopharma presents preclinical data on FGFR inhibitor candidate KIN-3248 - Kinnate Biopharma announced results from preclinical studies evaluating its lead Fibroblast Growth Factor Receptor inhibitor candidate, KIN-3248. These findings were presented during a virtual poster session at the joint JCA-AACR Precision Cancer Medicine International Conference that took place September 10-12, 2021. KIN-3248 is a next-generation, irreversible, small molecule pan-FGFR inhibitor designed to target cancer-associated FGFR2 and FGFR3 gene alterations, which are common oncogenic drivers seen in human cancers. KIN-3248 was developed to address both primary FGFR2 and FGFR3 oncogenic alterations and those predicted to drive acquired resistance to current FGFR-targeted therapies, including gatekeeper, molecular brake, and activation loop mutations observed in cancers such as intrahepatic cholangiocarcinoma and urothelial carcinoma. Kinnate anticipates filling an Investigational New Drug application for KIN-3248 with the U.S. Food and Drug Administration in the first half of 2022. The poster presentation, delivered by Aleksandra Franovic, Ph.D., Senior Director of Translational Medicine at Kinnate, highlights data which show that in biochemical and cellular assays, KIN-3248 exhibited nanomolar potency against all four wild-type FGFR family members but not against other non-FGFR kinases. Importantly, KIN-3248 was active against mutations associated with resistance to FGFR inhibitors both in the clinic and in experimental models, including the FGFR2 and FGFR3 gatekeeper, molecular brake, and activation loop mutations with less than a five-fold difference in IC50 values relative to corresponding wild-type receptors. In addition, dose-dependent inhibition of FGFR2- and FGFR3-driven human in vivo xenografts, including one with an acquired gatekeeper mutation, was attained with once-daily KIN-3248 treatment and was well tolerated. This efficacy was accompanied by both pharmacodynamic biomarker modulation and downstream pathway inhibition.

08:21 EDT Good Times Restaurants announces preliminary results of cash tender offer - Good Times Restaurants announced the preliminary results of its cash tender offer to purchase up to 1,413,000 shares of its common stock at a price per share of $4.60. The tender offer expired at 11:59 p.m., New York City time, on September 10. In accordance with the terms and conditions of the tender offer and based on the preliminary count by Broadridge Corporate Issuer Solutions, , the depositary for the tender offer, the Company expects to accept for payment, at a purchase price of $4.60 per share, a total of 333,241 shares properly tendered and not properly withdrawn before the expiration date, at an aggregate cost of approximately $1,532,908, excluding fees and expenses relating to the tender offer. The shares expected to be purchased represent approximately 2.6% of the Company's common stock issued and outstanding as of September 13. The number of shares expected to be purchased in the tender offer and the total purchase price are based on the assumption that all shares tendered through notice of guaranteed delivery will be delivered within the prescribed two trading day settlement period. The final number of shares to be purchased and the final total purchase price will be announced following the expiration of the guaranteed delivery period and the completion by the depositary of the confirmation process. Payment for the shares accepted for purchase pursuant to the tender offer, and the return of all other shares tendered and not purchased, if any, will occur promptly thereafter.

08:20 EDT Kratos Defense receives $338M sole source contract award from U.S. Air Force - Kratos Defense & Security Solutions announced that Kratos Unmanned Aerial Systems has been awarded a $338,071,466 Firm Fixed-Price, Cost-Plus-Fixed-Fee, and Time-and-Material contract for BQM-167A Air Force Subscale Aerial Target lots 17-21 production, out-of-warranty-repairs, and contractor logistics support. Work will be performed at a Kratos manufacturing facility. At the time of award funds in the amount of $30,499,362 were obligated. Air Force Life Cycle Management Center, Eglin Air Force Base, Florida, is the contracting activity.

08:19 EDT Mayfair Gold reports first results from Fenn-Gib step-out drill program - Mayfair Gold announced the first results from the Fenn-Gib step-out drill program to the east of the current deposit. The Fenn-Gib deposit, located in the Timmins region of Northeast Ontario, hosts a pit-constrained Indicated Resource of 2.08M ounces, with disseminated gold mineralization striking east-west on the Pipestone Fault over 1.25 kilometers and 300 meters wide at the west end. Drill hole FG21-168 intersected mineralization below two holes drilled in 2012 and 2017. Hole FG-12-27 intersected 0.78 g/t gold over 56.4m and hole FG-17-128 intersected 1.04 g/t Au over 40.7m. These holes, including hole FG21-168, are illustrated in the plan and section map available at https://mayfairgold.ca/fenn-gib/#drillplanmap§ions. In addition to the step-out drill program, Mayfair's infill drill program is continuing at the western section of the Fenn-Gib deposit. Highlights from that program include hole FG21-152, which returned 192.3m at a grade of 1.28 g/t gold from a downhole depth of 13.2m, including 35.0m grading 3.59 g/t Au. Hole FG21-152 was drilled from the same collar location and above Hole FG21-155 that returned 241.1m at a grade of 1.67 g/t Au. Expansion drilling supported by two drill rigs is also continuing below the shallow central section of the current conceptual open pit. Highlights include hole FG21-153, which intersected 233.0m at a grade of 1.05 g/t Au from a downhole depth of 352.7m, including 25.5m at a grade of 4.70 g/t Au. The exceptional high-grade intercept of 63.59 g/t Au over 5.0m from hole FG21-165, including 200.89 g/t Au over 1.5m, is also from below the central section of the current conceptual open pit. This intercept was at a downhole depth of 540.0m, which equates to approx. 400 vertical meters below surface. Additional drill results from the infill, expansion and step-out drill program will be announced as soon as they are received.

08:16 EDT Everi launches 'Borgata 777 Respin' custom-themed slot with BetMGM - Everi Digital, the online gaming division of Everi Holdings (EVRI), announced it has partnered with BetMGM to launch the custom-themed game "Borgata 777 Respin." Delivered via Everi's proprietary Spark Remote Game Server, the Borgata 777 Respin game is the first title Everi has developed in coordination with BetMGM. It is currently available through BetMGM Casino, Borgata Casino, and Party Casino in New Jersey, and on BetMGM Casino and Borgata Casino in Pennsylvania. BetMGM was born out of a partnership between MGM Resorts International (MGM) and Entain Plc.

08:16 EDT Splash Beverage Group expands distribution agreement with Eagle Brands - Splash Beverage Group announced it has expanded its distribution agreement with Eagle Brands which will now include Tapout non-alcoholic performance drink in addition to distributing Splash's Copa di Vino for the past 8 years and SALT Tequila since July 2021.

08:15 EDT Monopar Therapeutics expands phase 2b/3 VOICE clinical trial to Europe - Monopar Therapeutics announced it has received authorization to proceed with the Phase 2b/3 VOICE clinical trial in France. The trial, which began earlier this year in the US, is evaluating Validive to prevent the onset of severe oral mucositis in oropharyngeal cancer patients treated with chemoradiotherapy. The trial's rationale and design will be presented at the upcoming European Society for Medical Oncology Congress 2021. Monopar anticipates reaching the interim of the Phase 2b/3 VOICE trial in the first half of 2022. "Building on the numerous clinical sites we have activated in the US, we are pleased to receive authorization to proceed with the VOICE trial in France," said Octavio Costa, MD, Chief Medical Officer of Monopar. "Expansion to Europe marks another important milestone in this late-stage trial, and we anticipate dosing patients in France in the not too distant future with additional European countries to follow."

08:13 EDT Modine Manufacturing enters partnership with Advancoat - Modine Manufacturing announced that it has entered into a strategic partnership and license agreement with Advancoat, an engineering company dedicated to providing corrosion protection and indoor air quality solutions for the HVAC/R industry located in Pompano Beach, FL. This agreement allows Advancoat to provide Insitu coatings services to the South Florida market. As part of this agreement, Modine will close its Pompano Beach, FL facility. This decision is in line with the company's strategy to grow its coatings business by entering into strategic licensing agreements with high quality partners. This strategy will allow for the geographic expansion of the delivery of coatings products and services, while allowing internal resources to focus on new product development and overall channel management.

08:13 EDT Lantheus announces addition of PSMA PET imaging agent to NCCN guidelines - Lantheus Holdings announced that prostate specific membrane antigen positron emission tomography imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network Guidelines for prostate cancer. The NCCN Guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. Lantheus' product, PYLARIFY injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen level. PYLARIFY was approved by the U.S. Food and Drug Administration in May 2021 and remains the first and only commercially available PSMA-targeted PET imaging agent for prostate cancer. "We are extremely pleased that the NCCN panel of prostate cancer experts, who are dedicated to high-quality, high-value, patient-centered cancer care, have added PSMA-targeted PET imaging with piflufolastat F 18 in unfavorable intermediate, high and very high risk as well as recurrent disease to the updated 2021 guidelines, for the management of prostate cancer," said Bela Denes, MD, Vice President of Medical Affairs of Lantheus. "In addition to FDA approval, inclusion in the guidelines further validates PYLARIFY's performance and utility and will raise awareness within the medical community and payors of the potential impact of this novel PSMA-targeted imaging agent in the care of men with prostate cancer."

08:11 EDT Galecto treats first patient in Phase 2 trial of GB1211 - Galecto announced that the first patient has been treated with the galectin-3 inhibitor GB1211 in the Phase 1b/2a GULLIVER-2 trial. This trial marks the initiation of Galecto's clinical program for GB1211 in liver cirrhosis. Top line data from the full trial is expected in the second half of 2022. The GULLIVER-2 trial will assess the safety, tolerability, pharmacokinetics and efficacy of GB1211 in up to 54 participants, including liver cirrhosis patients with moderate or severe hepatic impairment. The trial will randomize liver cirrhosis patients of any etiology and evaluate the impact of GB1211 on liver fibrosis and liver function.

08:11 EDT OncoCyte to present new data on DetermalIO from NeoTRIPaPDLI trial - Oncocyte announced that it will present new data from ongoing clinical research evaluating the 27-gene DetermaIO assay used to determine the likelihood of response to IO therapies at the upcoming European Society for Medical Oncology Congress, taking place virtually September 16th-21st, 2021. Oncocyte will be distributing a data press release after market close on September 20th, 2021, summarizing the presented results from the abstract. The Company's DetermaIO assay is a precision diagnostic designed to determine the likelihood of response to IO therapies, and is the first and only test to measure the entire tumor microenvironment. By evaluating the entire TME, the test can help identify patients that are primed to respond to IO therapy, as well as patients who may not respond as well, allowing for physicians and their patients to have data-driven conversations about the choices available to them.

08:10 EDT Alkami closes acquisition of MK Decision Systems - Alkami Technology announced it has finalized its acquisition of MK Decisioning Systems, a technology platform and provider for digital account opening, credit card, and loan origination solutions. The acquisition reinforces and expands Alkami's position as a best-of-breed digital banking platform provider that designs secure solutions across the user journey, from acquisition to engagement to conversion. In acquiring MK, Alkami is expected to expand its total addressable market while gaining new cross-selling opportunities among a larger installed base. All employees from the newly acquired MK, located in San Diego, California and throughout the US, have been retained by Alkami as part of the transaction. Khalsa will be the Vice President and General Manager of the newly formed Digital Account Opening and Loan Origination Solutions Team within Alkami. The purchase price for MK consists of $20M of proceeds at close and an opportunity for MK to earn up to an additional $25M in consideration contingent upon the achievement of certain milestones in 2022 and 2023. Alkami expects the acquisition to be immaterial to its financial results for the third quarter of 2021.

08:09 EDT Worksport outlines additional details on collaboration with Ontario Tech - Worksport outlined additional details on its collaboration with Ontario Tech University to develop Terravis Energy's NP hydrogen solutions. This initiative is part of a two-year, $2.3 million project funded equally by Worksport and the Canadian Government that will incorporate efforts and resources from Worksport, Terravis Energy, an OTU research team led by Dr. Sheldon Williamson, and the Canadian government. The collaboration will include R&D teams of professors, PhD candidates, and post-Doctoral fellowships in a collective effort to bring groundbreaking, grid-independent, green energy solutions to market. The teams will also have full access to the unique, world-renowned Ontario Tech-Automotive Center of Excellence, the first commercial automotive research, development, and innovation center of its kind in the world. The facility includes a comprehensive array of testing equipment - including one of the largest and most sophisticated climatic wind tunnels on the planet. The OTU-ACE climatic wind tunnel is a place where world-class researchers and engineers collaborate to create, test, and validate paradigm-shifting innovations. General Motors, for example, used the OTU-ACE's climatic wind tunnel to test its Hummer EV. The Company's research with Ontario Tech University thus far has uncovered what Company management believes will be new, lucrative paths to clean energy adoption by the market, possibly paving the way for additional backing from the Canadian Government. Among the many breakthroughs that have come from this collaboration to date is the system's charging rate enhancement modularity. This development enables increased charging capabilities as battery technologies evolve, and it represents a significant milestone in Terravis Energy's positioning as an industry innovator. In addition to use of the OUT-ACE, the research teams will have access to cutting-edge facilities and research equipment in the Advanced Storage Systems and Electric Transportation lab, which boasts equipment such as battery pack and cell simulators, programmable loads, regenerative grid simulators, and advanced thermal chambers. This specialized equipment is unique and available only to Prof. Williamson's lab. Lastly, the Company will also have access to the world-renowned Clean Energy Research Lab.

08:07 EDT Amdocs selected by Orange as monetization engine for their 5G network - Amdocs announced that it has been selected by Orange to provide the business support systems for Europe's first 5G Stand Alone experimental cloud network launched in July in Lannion, France. The data- and AI-driven software-enabled network, automated and cloud-native, is a two-year project that aims to ramp up to encompass several hundred users by the end of 2021. The network utilizes Open RAN technology and will act as Orange's blueprint for the next generation of more efficient and agile networks relying on AI and data.

08:07 EDT Five Star reports August month- end occupancy up 320 basis points to 73.7% - Five Star Senior Living (FVE) or Five Star announced progress on its strategic plan and provided certain business updates. August month end occupancy in Five Star's owned communities was 73.7%, an increase of 320 basis points compared to July month end occupancy. August average occupancy in Five Star's owned communities was 70.0%, an increase of 80 basis points compared to the July average occupancy. In the 120 communities Five Star will continue to manage for Diversified Healthcare Trust (DHC), or the retained communities, August month end occupancy was 74.7%, an increase of approximately 100 basis points compared to the July month end occupancy. August average occupancy in the retained communities was 73.4%, an increase of 50 basis points compared to July average occupancy. FVE also provided an update on the repositioning of its senior living management services as part of its strategic plan announced in April 2021, including the transition of 108 smaller senior living communities to other operators. FVE has now completed 62 of 108 planned transitions to other third-party operators and plans to fully complete the transition of the 108 communities by year end. Additionally, FVE reported that all community and clinic employees are now in compliance with its previously announced requirement that those employees who work in or visit its communities or Ageility clinics as part of their responsibilities be fully vaccinated against COVID-19, with only 4.3% of employees voluntarily terminating their employment.

08:06 EDT Absolute Software CMO Sandra Toms to depart, Joel Windels to succeed - Absolute Software announced Joel Windels has been promoted to CMO to lead Absolute's marketing organization, drive demand generation, and expand brand marketing. Windels joined Absolute in July through the NetMotion acquisition. He previously served on the senior executive team as CMO at NetMotion. As part of this leadership transition, Ameer Karim, who held the position of executive VP of product management, and Sandra Toms, who held the position of CMO, will be leaving Absolute.

08:05 EDT Amdocs Media's Vubiquity renews multi-year contract with izzi - Vubiquity, part of the Amdocs Media Division, announced a multi-year renewal agreement with izzi, a leading cable TV operator in Mexico. As part of this agreement, Vubiquity will continue to provide content licensing and processing for the izzitv service. As part of the agreement, Vubiquity offers a full suite of content acquisition, curation and content management services to support izzi's platform.

08:03 EDT Danimer Scientific names Deborah McRonald as Chief Corporate Development Officer - Danimer Scientific announced that Deborah McRonald has joined the Company to serve in the newly created position of Chief Corporate Development Officer. With many years of experience leading business development and technology licensing initiatives across the pharmaceutical, consumer goods, maternal and infant nutrition, and food and beverage industries, McRonald will focus on developing external collaborations that drive revenue and fulfill the Company's mission of reducing plastic waste across the globe. These collaborations are expected to include potential licensing or joint-venture agreements with various partners to further increase market applications for Danimer's technology and materials, as well as to enhance the Company's returns on invested capital. "As our rapid growth plans progress, we will continue developing a strong portfolio of customer and industry collaborations, and Deborah is the ideal candidate to execute this strategy," said Stephen E. Croskrey, Chief Executive Officer at Danimer Scientific. "Her years of experience at Nestle establishing many types of partnerships, including new forms of consumer packaging, will be invaluable in guiding our own strategic collaborations. We are excited to welcome Deborah to the Danimer family."

08:02 EDT Medigus says Revoltz commences prototype manufacturing of micromobility vehicle - Medigus announced that Revoltz, its EV joint venture, has begun the prototype manufacturing of its micro mobility vehicle. The production has commenced in China together with Mr. Weijian Zhou, one of Revoltz partners. Weijian Zhou is a manufacturer of high-end scooters, E-mobility and Skiing Machines. Mr. Zhou's operations are equipped with advanced machining and inspection facilities, an R&D center, and a Training Institute. Revoltz recently completed the preliminary design and functional prototype of Model One, its micro-mobility vehicle for last mile and food delivery, which is designed to facilitate efficient delivery of smaller items in urban environments while maintaining low and immediate transportation costs. A three-wheeled chassis with a wide platform design provides maximum safety for the rider as well as complete mobility in imperfect road conditions. The Model One design includes two loading surfaces, front and rear, each of which can be used flexibly with interchangeable modules, depending on the customer's needs. The model is designed to carry two-and-a-half times the cargo of a traditional scooter. The newly manufactured prototypes will be used by Revoltz to further advance its development and to approach potential commercial partners.

07:44 EDT Academy Sports announces secondary offering, concurrent share repurchase - Academy Sports and Outdoors announced that certain of its stockholders that are affiliates of Kohlberg Kravis Roberts & Co intend to offer for sale in an underwritten secondary offering 18,645,602 shares of common stock of Academy pursuant to a registration statement filed by Academy with the U.S. Securities and Exchange Commission. No shares are being sold by Academy. The Selling Stockholders will receive all of the proceeds from this offering. Academy announced that, subject to the completion of the offering, it intends to repurchase from the underwriters, out of the 18,645,602 shares of common stock, a number of shares having an aggregate purchase price of up to $200 million at a price per share equal to the price at which the underwriters will purchase the shares from the Selling Stockholders. Any shares repurchased by Academy will be pursuant to its recently announced $500 million share repurchase program and will be retired. The closing of the share repurchase is conditioned on, and expected to occur simultaneously with, the closing of the offering, subject to the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the share repurchase.

07:43 EDT Regal Beloit, Rexnord: Close of PMC combination to occur on October 4 - Regal Beloit (RBC) and Rexnord (RXN) announced that they expect to complete the proposed combination of the Process & Motion Control Business of Rexnord with Regal through a Reverse Morris Trust transaction on October 4, subject to satisfaction or waiver of the applicable closing conditions. Following completion of the transactions, (a) Regal will change its name to "Regal Rexnord Corporation" and its shares of common stock will trade on the NYSE under the ticker symbol "RRX" and (b) Rexnord Corporation will change its name to "Zurn Water Solutions Corporation" and its shares of common stock will trade on the NYSE under the ticker symbol "ZWS". Regal and Rexnord will provide additional details regarding the expected closing in the coming weeks.

07:41 EDT Motorola networking products launch in India - Minim announced that the Motorola MH7020 Whole Home WiFi Mesh System is now available in India. With this launch, Indian consumers will also receive a free upgrade to its new mobile app, motosync, powered by Minim. Together, the Motorola MH7020 mesh system and motosync app create exceptional coverage, network security, performance, and control at the competitive price of INR 7,999.00, INR 13,999.00, or INR 19,999.00.

07:39 EDT aTyr Pharma announces positive data from Phase 1b/2a trial for ATYR1923 - aTyr Pharma announced positive results from its Phase 1b/2a double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in 37 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity. Additionally, the study demonstrated consistent dose response for ATYR1923 on key efficacy endpoints and improvements compared to placebo, including measures of steroid reduction, lung function, sarcoidosis symptom measures and inflammatory biomarkers. Key Safety and Clinical Efficacy Findings for ATYR1923: safe and well-tolerated at all doses; no dose-relationship with most common adverse events associated with underlying disease; no drug-related serious adverse events; no signal of immunogenicity; dose response and consistent positive findings across key efficacy endpoints; steroid reduction of 58% overall from baseline and 22% relative reduction compared to placebo in steroid usage post taper in the 5.0 mg/kg treatment group; complete steroid taper to 0 mg achieved and maintained for 33% of patients in the 5.0 mg/kg treatment group compared to no patients in any other group; absolute improvement in forced vital capacity as a measure of lung function at week 24 of 3.3% in the 5.0 mg/kg treatment group compared to placebo, with an improvement in FVC of greater than 2.5% considered clinically meaningful; clinically meaningful improvement over placebo observed for dyspnea, cough, fatigue and the King's Sarcoidosis Scores for Lung and General Health in 5.0 mg/kg treatment group; dose dependent trends of improvement in key inflammatory biomarkers compared to placebo including IL-6, MCP-1, IFN-gamma, IP-10 and TNFa as well as key sarcoidosis markers including ACE, IL-2Ra and SAA with tightest control in the 5.0 mg/kg treatment group; and FDG-PET-CT was not evaluable due to incomplete data primarily caused by operational issues related to the COVID-19 pandemic

07:37 EDT Lantheus, RefleXion announce development, commercialization collaboration - Lantheus announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus' prostate-specific membrane antigen-targeted positron emission tomography imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy in prostate cancer using the RefleXion X1 platform. The RefleXion X1 integrates PET technology into a therapeutic radiation delivery device to enable radiation to be guided in real-time to tumor sites localized by the PET tracer. This approach has the potential to use the tumor's biology, as characterized by the PET tracer, to guide radiation delivery to multiple cancer sites within a patient in a single session. The Development and Commercial Collaboration Agreement, which will be managed by a Joint Steering Committee, is focused on obtaining approval to treat patients with BgRT guided by piflufolastat F 18 in the United States. Under the terms of the agreement, Lantheus will contribute to the cost of RefleXion's registrational program. Additionally, the parties will share in the upside created by this collaboration. Further terms of the agreement were not disclosed.

07:35 EDT Air Worldwide updates losses for Hurricane Ida to $20B-$30B - Extreme event modeling firm AIR Worldwide updated its insured loss estimates for Hurricane Ida after analyzing the inland flood impacts across the entirety of its track, including the Northeast. AIR now estimates that Ida's insured industry losses will range from $20 billion to $30 billion. AIR estimates wind and storm surge losses will range from $17 to $25 billion, and private-market insured losses from inland flooding will range from $2.5 billion to $5 billion. Included in the estimates are losses to onshore residential, commercial, industrial properties, and automobiles for their building, contents, and time element coverage, as well as estimated insurance take-up rates for wind and flood across the entirety of Ida's track, including the flooding that occurred in the Northeast. AIR's losses do not include any estimate of losses from the National Flood Insurance Program, or any losses from offshore assets. The industry loss estimates also reflect an adjustment to account for increased material and other repair costs in the current construction market.

07:34 EDT Federal Realty acquires Twinbrooke Shopping Centre in Fairfax, Virginia - Federal Realty announced the acquisition of a 100% interest in Twinbrooke Shopping Centre, a 110,000 square foot grocery anchored neighborhood shopping center on 10 acres located in Fairfax, Virginia. The Property is situated at the intersection of Braddock Road, a main east-west thoroughfare providing access to the DC beltway, and Twinbrook Road. Federal sourced the acquisition off-market for a purchase price of $33.8M cash. In 2021, Federal Realty has acquired 5 properties totaling 1.9M square feet and 135 acres at a gross value of $441M of which Federal will own an average 82% interest.

07:33 EDT Provention Bio provides update on teplizumab BLA resubmission - Provention Bio provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter issued to the company by the FDA on July 2. The company has completed the collection of data from a PK/PD substudy in the ongoing PROTECT Phase 3 trial in newly diagnosed T1D patients to determine comparability between the company's planned commercial drug product and drug product originating from drug substance manufactured for historical trials of teplizumab. During ongoing informal discussions with the FDA to finalize and agree upon the design of the population PK model that will generate the PK parameters comparing drug products, the FDA has recommended that the company request a formal Type A meeting and submit briefing documents related to the population PK model. The objective of this meeting with the FDA is to agree on the PK model's design prior to the company populating the model with relevant PK data collected from the PROTECT substudy. The company is working towards a request and submission to allow this Type A meeting to occur in the fourth quarter of this year. Additionally, the company disclosed preliminary PD marker information upon therapeutic dosing of teplizumab from the substudy data that the company believes are supportive, although not determinative, of comparability between the two drug products. The FDA has not yet opined on these data or their significance, and the company looks forward to discussing with the FDA. These PD markers include lymphocyte counts, CD3 receptor occupancy and T-cell activation. The company also recently completed a Type A meeting with the FDA to discuss several additional considerations related to product quality that were cited in the CRL. The company continues to believe that the product quality CRL considerations have either already been addressed by prior amendments to the BLA or are addressable in the short term. As it relates to the deficiencies noted during the recent general inspection at a fill/finish facility used by the dcompany mentioned in the CRL, this facility's inspection has since been closed out by the FDA in August of 2021. "We believe we are making significant progress in our work to address the observations cited by the FDA in the CRL for teplizumab we received in July and we will continue to work with the sense of urgency that the patient community and our investors expect of us," said Ashleigh Palmer, co-founder and CEO of Provention Bio. "We are encouraged by our interactions with the FDA and look forward to finalizing, to the FDA's satisfaction, the design of the population PK model that will be used to further determine comparability, as well as evaluate the clinical relevance of the outputs. Additionally we are encouraged by the consistent incremental PD marker data that we are sharing today."

07:31 EDT PharmaTher focused on building specialty ketamine-based pipeline - PharmaTher is focused on building a specialty ketamine-based product pipeline. The Company has selected a U.S.-based GMP contract development and manufacturing organization with extensive experience in the development, production and supply of clinical and commercial controlled substance sterile products. PharmaTher will work with the CDMO to develop the Company's proprietary ketamine drug product to support future clinical studies and global commercial supply. It is expected that the proprietary ketamine drug products will be available for FDA Phase 3 clinical studies and commercialization in H2-2022. Proprietary Microneedle Patch The Company entered into a co-development agreement with TSRL, Inc. to jointly develop the patented hydrogel-forming microneedle patch delivery technology. This allows the Companies to control the manufacturing and supply of microneedle patches for their respective clinical and commercial drug programs. PharmaTher is focused on incorporating psychedelics and TSRL is focused on incorporating antiviral medications in a microneedle patch with the potential to improve the safety, efficacy and compliance of these compounds that currently must be taken orally, inhaled, injected and intravenously. Recent activities included the tech transfer for scale-up and manufacturing of clinical supplies to a GMP contract research lab and a pre-IND meeting with the FDA that achieved agreement with the agency on proposed 505(b)2 product development plans. The Company aims to validate non-clinical and clinical production of the microneedle patch by October 2021 and begin non-clinical and clinical manufacturing supply at the end of 2021. The Company expects to enter into Phase 1 and 2 clinical studies in 2022 to evaluate its microneedle patch in delivering ketamine, KETABET, psilocybin, DMT, MDMA and LSD.

07:28 EDT PharmaTher to focus on advancing three developments through Phase 2 studies - PharmaTher Holdings is pleased to provide a product pipeline update and anticipated milestones for Q4-2021 and 2022 including ongoing FDA Phase 2 clinical study programs, microneedle patch delivery programs for psychedelics, and clinical, commercial manufacturing and supply for its proprietary ketamine and microneedle patch products. For the rest of 2021, PharmaTher will focus on advancing three promising developments through FDA Phase 2 clinical studies: Ketamine for Parkinson's Disease: The FDA's approval to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease triggered clinical program execution. The Company has completed its clinical trial start-up activities and selection of essential vendors including project management, central laboratory, clinical supply kits and logistics, data management and biostatistics, and clinical site management and monitoring. Clinical trial drug product and active placebo have also been obtained. More importantly, the Company has selected ten clinical sites in the U.S. to participate in the Phase 2 clinical study. Patient screening has begun and the Company expects patient enrollment to support the delivery of clinical results in Q4-2021. If the Phase 2 clinical study is positive, the Company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a Phase 3 clinical study under the 505(b)2 regulatory pathway in the first half of 2022. KETABET for Treatment-Resistant Depression The Company has finalized the Phase 2 clinical study protocol to evaluate KETABET for treatment-resistant depression. The Company is working with its scientific and clinical advisor, Dr. Maurizio Fava, MD, with the aim to complete the IND and file it with the FDA in early October. With the overlap of the clinical operations from the Parkinson's disease study, the Company has already activated start-up activities and identified potential clinical sites to screen and enroll patients for the proposed Phase 2 clinical study in Q4-2021. The aim is to share initial clinical results by the end of this year. Assuming the Phase 2 clinical study is positive, the Company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a Phase 3 clinical study under the 505(b)2 regulatory pathway in the first half of 2022. Ketamine for Amyotrophic Lateral Sclerosis: The Company has been granted orphan drug designation by the FDA for ketamine to treat ALS and along with its clinical advisors, has finalized the Phase 2 clinical study protocol. The IND application for this study is in process and will be filed with the FDA in October 2021 with patient enrollment targeting Q1-2022. PharmaTher has an exclusive license agreement with the University of Kansas for the intellectual property protecting the potential use of ketamine to treat ALS. Preclinical research has shown that the administration of ketamine preserves muscle function in advancing ALS and could potentially increase life expectancy when given in the early stages of muscle decline.

07:23 EDT Gilat Satellite receives $12M service agreement for operation in Peru - Gilat Satellite Networks announced that Gilat received a $12M service award for recurring revenues from broadband services in Cusco, Peru. Operation & Maintenance for a three-year period will be provided for the regional broadband transport network. This contract of the regional broadband service project follows the completion of the construction phase and successful acceptance test, granted for Cusco, earlier this year. "The operation & maintenance services for the transport network of the Cusco region is an additional step in materializing Gilat's strategy to provide this service to the transport networks of all six regions that Gilat operates," said Arieh Rohrstock, Corporate SVP and General Manager Gilat Peru. "We see this significant achievement as opening the door for potential growth in the additional regions and a significant milestone in bringing us closer to achieving our target of $50 million dollars in annual recurring revenues from Peru."

07:19 EDT LMP Automotive to purchase 85% interest in Alan Jay Automotive - LMP Automotive announced its entry into definitive acquisition agreements to purchase an 85% interest in the Alan Jay Automotive Network, a 12-dealership group in Florida, along with the associated real estate. The transaction: is expected to close in the fourth quarter of this year; has an Aggregate Purchase price of approximately $50M for goodwill expected to be funded through a combination of cash on LMP's balance sheet, up to $25M in common stock and debt financing; and an Aggregate Real estate purchase price of approximately $44.1M. Richard Aldahan, LMP's Chief Operating Officer, stated, "First, I would like to welcome Alan Jay Wildstein, Michael Witham and James Lizotte to the LMP organization. Upon close, Alan Jay Wildstein will be Regional Vice President at LMP, Partner, as well as Dealer Operator of the acquired dealership group. Michael Witham will continue to be the group's Chief Operating Officer, along with James Lizotte who will be Vice President of Operations, each of whom have over 30 years' experience in the automotive industry. I look forward to working with each of them in our future partnership. This acquisition will further expand our management team and Southeast footprint. We intend to continue expanding aggressively in this region as we are seeing a record amount of interest in our dealer partner model."

07:18 EDT ADC Therapeutics receives orphan drug designation in Europe for Zynlonta - ADC Therapeutics announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma, DLBCL. "This Orphan Drug Designation recognizes the significant unmet need in patients with diffuse large B-cell lymphoma in the European Union " said Joseph Camardo, MD, Senior Vice President and Chief Medical Officer of ADC Therapeutics. "We are committed to providing global access to ZYNLONTA for as many patients as may benefit. This designation is an important step in our collaboration with EMA for our marketing authorization in the EU." Orphan Drug Designation in the EU is granted by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products . It is intended to encourage the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. If approved for marketing, this designation will provide ten years of marketing exclusivity and also provide special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees.

07:15 EDT Mesa Air reports 32,501 block hours in August - Mesa Airlines reported 32,501 block hours in August 2021, a 73.4 percent increase from August 2020 as a result of continued increased summer flying and the relaxation of certain COVID restrictions. The Company also reported a controllable completion factor of 99.71 percent and 99.66 percent for its American and United operations, respectively.

07:15 EDT GT Biopharma advances GTB-3650 into IND-enabling studies - GT Biopharma announces the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550. "We look forward to advancing GTB-3650 toward the clinic" noted Greg Berk, M.D., GT Biopharma's President of R&D and Chief Medical Officer. "This transition marks the next logical evolution of our TriKE platform. As the company focuses its resources on the most promising pipeline candidates, GTB-3650 will now be able to take advantage of the strong evidence gathered from our first-generation pilot TriKE program. Complementing this development advance, has been the transition of all manufacturing processes to Cytovance Biologics, a leading specialty cGMP contract manufacturing organization. We have now achieved another strategic milestone consistent with our mission to advance novel immuno-oncology drugs to patients with advanced cancers", commented Dr. Berk.

07:13 EDT Betterware de Mexico announces $50M share repurchase program - Betterware de Mexico announced that as part of the company's long-term strategy to maximize stockholder value, its Board of Directors authorized the repurchase of up to $50M of the company's common stock. Betterware intends to have the stock repurchase plan in place until December 31, 2022.

07:13 EDT Purple Biotech to present overview of ongoing Phase 1b/2 trial of CM24 - Purple Biotech (PPBT) provided an update on its ongoing Phase 1b/2 clinical trial of CM24, a monoclonal antibody blocking CEACAM1, in combination with nivolumab, a PD-1 inhibitor, in advanced cancer patients, with expansion cohorts in subjects with non-small cell lung cancer and in combination with nivolumab and nab-paclitaxel in pancreatic cancer. In a Trials in Progress poster at the ESMO 2021 Congress, which will be held on September 16-21, 2021, Purple Biotech will present an overview and the design of the ongoing Phase 1b/2 study. The poster is titled, "A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer." Top-line data from the first dose cohort of CM24 10mg/kg included a partial response demonstrated in a patient with refractory advanced pancreatic cancer previously treated with two lines of therapy following two courses of treatment with CM24 in combination with nivolumab 480mg/kg. Additionally, there were no dose-limiting toxicities or serious adverse events observed in any of the three patients enrolled in the first cohort of the study. Enrollment in the second dose cohort has successfully concluded. Moreover, the Phase 1b/2 study is being expanded to additional sites in the U.S. and Israel. The study is a Phase 1b/2 clinical trial with expansion cohorts in subjects with NSCLC and pancreatic cancer. CM24 is dose escalated from 10mg/kg, in combination with nivolumab, 480mg q4w, in Phase 1b, in patients with NSCLC, pancreatic cancer, ovarian carcinoma, colorectal adenocarcinoma, melanoma, or thyroid carcinoma, with the primary objective of evaluating safety, PK and determining the recommended Phase 2 dose. In the Phase 2 component, patients with NSCLC will be treated with CM24 and nivolumab after first-line immuno-oncology failure, and patients with advanced/metastatic pancreatic adenocarcinoma will be treated with CM24, nivolumab, and nab-paclitaxel after first-line therapy failure, with study endpoints being safety and preliminary efficacy. CEACAM1 level of expression, as well as a number of other immune, biochemical and adhesion-related molecules, will be evaluated as potential biomarkers in the study. The trial is being conducted under a clinical collaboration and supply agreement with Bristol Myers Squibb (BMY). Purple Biotech is the sponsor of the trial.

07:11 EDT Pretium says resource expansion drilling continues to intersect high-grade gold - Pretium Resources announced that it continues to intersect high-grade gold mineralization in Phase 3 of the North Block resource expansion drill program at the Brucejack Mine in British Columbia. Phase 3 of the North Block resource expansion drill program was initiated to follow-up on the high-grade gold intersected directly to the north of the Valley of the Kings deposit during Phase 1 and Phase 2 of the North Block drill program. Phase 3 results include seven intersections assaying above 1,000 grams per tonne gold. Drill hole VU-3255 assayed 493.2 grams per tonne gold over 15.0 meters, including 7,360 grams per tonne gold over 1.0 meter. Drill hole VU-3242 assayed 676.8 grams per tonne gold over 7.0 meters, including 3,150 grams per tonne gold over 1.5 meter. High-grade gold mineralization was intercepted up to 450 meters from the current Valley of the Kings resource shell and up to 300 meters from the West Zone resource shell. One drill hole from each drill fan was extended to test the exploration potential to the north of the North Block Zone. These extended holes intersected stockwork veining and high-grade gold mineralization along trend from the West Zone. An intersection from drill hole VU-3252 assayed 3,660.0 grams per tonne gold over 1.0 meter at 330.5 meters down hole. The North Block Zone is located directly to the north of the Valley of the Kings deposit. The resource expansion exploration program is designed to test for Valley of the Kings-style mineralization to the north and at depth. Phase 3 of the program was drilled from the 1150 and 1070 Levels in the mine, targeting an area extending up to 450 meters north of the current Valley of the Kings resource shell. Phase 3 of the North Block resource expansion program comprised 25,154 meters in 85 drill holes. Drilling from the 1150 Level intersected the extension of the Domain 13 Stockwork, which is currently being mined in the Valley of the Kings. Drilling from the 1070 Level intersected the recently identified corridor of gold mineralization in the footwall of the Domain 13 structure, featuring coarse electrum in northwest oriented quartz-carbonate veins within a broader halo of lower grade gold mineralization. Significant drill results are shown below: Hole VU-3042 intersected 93.4 grams per tonne gold over 34.5 meters, including 3,140 grams per tonne gold and 2,000 grams per tonne silver over 1.0 meter. Hole VU-3241 intersected 133.7 grams per tonne gold over 6.0 meters, including 3,590 grams per tonne gold and 2,680 grams per tonne silver over 1.0 meter. Hole VU-3242 intersected 676.8 grams per tonne gold over 7.0 meters, including 3,150 grams per tonne gold and 1,870 grams per tonne silver over 1.5 meters. Hole VU-3249 intersected 5.3 grams per tonne gold over 13.5 meters, including 3,660 grams per tonne gold over and 3,040 grams per tonne silver over 1.0 meter. Hole VU-3255 intersected 493.2 grams per tonne gold over 15.0 meters, including 7,360 grams per tonne gold and 4,400 grams per tonne silver over 1.0 meter.

07:10 EDT Aterian up 17% in pre-market trading at $13.77 per share - Shares of Aterian are up about 17% at $13.77 in pre-market trading following Friday's 16% advance. The stock is in the top 5 highest trending tickers on StockTwits in terms of message volume over the past 24 hours.

07:09 EDT Plus Therapeutics appoints Norman LaFrance as CMO - Plus Therapeutics announced the appointment of Norman LaFrance, M.D. to the position of Chief Medical Officer, or CMO, and Senior Vice President. Dr. LaFrance's appointment begins on or around December 8, 2021 and he joins the Company with nearly 40 years of experience as a nuclear medicine physician and as an executive in the pharmaceutical and healthcare industries. He was most recently Chief Medical Officer, Senior Vice President, at Jubilant Pharma, responsible for all Pharma Medical & Regulatory Affairs activities.

07:08 EDT B. Riley Financial to acquire additional shares of DoubleDown - B. Riley Financial (RILY) announced it intends to commence a cash tender offer, through its wholly owned subsidiary, to purchase additional shares of DoubleDown Interactive (DDI). B. Riley intends to commence a tender offer to purchase up to 2M American Depositary Shares, each representing 0.05 of a common share of DDI, at $18.00 per ADS. Terms of the tender offer are expected to be finalized shortly with the tender offer to formally commence by late September.

07:06 EDT Cedar Fair hires Ty Tastepe as Chief Information Officer - Cedar Fair Entertainment announced that Ty Tastepe has joined the company in the newly created role of senior vice president and chief information officer. He will be based at the company's office in Charlotte, North Carolina, and will report to President and Chief Executive Officer Richard A. Zimmerman.

07:05 EDT Adaptimmune announces data from its Phase 1 SURPASS trial - Adaptimmune Therapeutics announced updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the upcoming European Society for Medical Oncology, or ESMO, annual meeting. "It is no longer a question of whether our SPEAR T-cells are effective against a range of MAGE-A4 expressing tumors - they undoubtedly are. Now, our focus is on turning them into approved therapies. This begins with ongoing recruitment in this SURPASS trial for people with lung, bladder, gastroesophageal, head and neck, and now ovarian cancer, and continues with the recently initiated SURPASS 2 trial in esophageal and EGJ cancers," said Adrian Rawcliffe, Adaptimmune's CEO. "These data bring us closer to identifying further indications to take into late-stage development and confirm our expertise in developing and enhancing cell therapies. ADP-A2M4CD8 does exactly what we designed it to do - kill cancer cells and more effectively engage the broader immune system to deliver improved potency and clinical benefit." Results from Phase 1 SURPASS trial: all patients had advanced metastatic disease and had received multiple prior regimens of systemic therapy; the overall response rate was 36% and the disease control rate was 86%; there was a complete response reported in a patient with ovarian cancer, which remains ongoing at 6 months post-infusion. Conclusions from the Phase 1 SURPASS Trial Data at ESMO: initial efficacy and durability data are "encouraging" with responses across five different solid tumors including a complete response in a patient with ovarian cancer ongoing at 6 months; the safety profile of the next-generation ADP-A2M4CD8 cell therapy was acceptable; data confirm preclinical observations that the enhanced TCR interaction in ADP-A2M4CD8 results in a more potent product; safety and efficacy, including duration of response, will continue to be evaluated in the ongoing SURPASS trial, which is enrolling eligible patients with gastroesophageal, head and neck, lung, bladder, and ovarian cancers; and a Phase 2 trial, SURPASS-2, has initiated for patients with esophageal and EGJ cancers

07:04 EDT Docebo CFO Ian Kidson retires, Sukaran Mehta appointed interim immediately - Docebo announced Ian Kidson's retirement as Chief Financial Officer of Docebo. Sukaran Mehta, CPA, CA, ACA, Vice President of Financial Reporting, has been appointed as Interim Chief Financial Officer effective immediately until a permanent replacement is named. Mr. Kidson will continue to be employed by Docebo until October 11, 2021. He will then be available on a consulting basis until December 31, 2021 to provide support as needed and ensure an orderly transition. "Ian joined Docebo to help us prepare and execute our IPO and on behalf of the Company, we thank him for his contributions during a period of unprecedented progress and growth," said Claudio Erba, CEO. "We have a great foundation today, with an experienced finance team led by Sukaran that enables this orderly transition as we position Docebo for our next phase of growth."

07:03 EDT Instil Bio receives IND clearance to initiate Phase 2 trial of ITIL-168 - Instil Bio reported clearance of its Investigational New Drug application from the U.S. Food and Drug Administration to initiate DELTA-1, a global Phase 2 clinical trial of ITIL-168 in patients with advanced melanoma whose disease has relapsed after a PD-1 inhibitor and, if positive for a BRAF-activating mutation, a BRAF inhibitor. The DELTA-1 trial was expanded during the IND review process, in consultation with FDA, to include additional populations of patients with advanced melanoma. Cohorts 2 and 3 will enroll patients who discontinued PD-1 inhibitor therapy due to intolerable toxicity and patients who had an unsatisfactory response to prior PD-1 inhibitor but have not yet experienced disease progression, respectively. Topline safety and efficacy results are expected in 2023 and, if positive, are anticipated to support the submission of a biologics license application to the FDA in 2023 and a Marketing Authorization Application to the European Medicines Agency in 2024.

07:02 EDT Marriott Vacations sees Q3 contract sales at lower end of $380M-$410M - In its Vacation Ownership business, the company continues to experience strong occupancies at most of its resorts, despite modestly elevated cancellation trends in certain markets due to the COVID-19 delta variant and the fires impacting Lake Tahoe. As a result, the company expects contract sales for the third quarter of 2021 to be towards the lower end of original guidance of $380M-$410M, continuing to illustrate the resiliency of its leisure-focused business model. "With our product offerings resonating with customers more than ever, we expect our Adjusted EBITDA in the third quarter to approach 2019 levels," said Stephen P. Weisz, CEO.

07:01 EDT Bristol-Myers: Opdivo plus Yervoy shows durable OS at three years - Bristol Myers Squibb announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo plus Yervoy compared to platinum-based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma, regardless of histology. With a minimum follow-up of three years: Among patients treated with Opdivo plus Yervoy, 23% were alive at three years, compared to 15% of patients treated with chemotherapy. Treatment with the dual immunotherapy combination continued to show a reduction in the risk of death, and improvement in median overall survival, the trial's primary endpoint, vs. chemotherapy. The safety profile for Opdivo plus Yervoy remained consistent with previously reported data in first-line MPM, with no new safety signals identified. These data will be presented on September 17, 2021 at 13:40 CEST/7:40 a.m. EDT during the Proffered Paper session at the 2021 European Society for Medical Oncology Virtual Congress. At three years of follow-up and approximately one year of being off treatment per protocol, more patients who responded to Opdivo plus Yervoy remained in response than those treated with chemotherapy, and duration of response was longer with the dual immunotherapy combination, regardless of histology: 28% of patients who responded to Opdivo plus Yervoy remained in response at three years compared to no patients in the chemotherapy arm. Those treated with the dual immunotherapy combination had a median DOR of 11.6 months, compared to 6.7 months with chemotherapy. Objective response rate in patients treated with the combination was comparable to chemotherapy.

06:52 EDT SQZ Biotechnologies announces first clinical translation of TAC platform - SQZ Biotechnologies announced that the first clinical translation of the company's Tolerizing Antigen Carrier platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment. The company anticipates an IND filing in the third quarter of 2022. In preclinical models, SQZ TACs have demonstrated the ability to induce multi-mechanism antigen-specific tolerance relevant to many immune mediated disorders. The company's celiac disease program may support expansion into additional autoimmune diseases.

06:49 EDT Lazard reports preliminary AUM $282.8B as of August 31 - Lazard that its preliminary assets under management as of August 31 totaled approximately $282.8B. The month's AUM included market appreciation of $5B, foreign exchange depreciation of $0.5B and net outflows of $17M.

06:46 EDT Booz Allen to acquire Tracepoint, terms not disclosed - Booz Allen Hamilton announced that it has completed the acquisition of Tracepoint, a digital forensics and incident response company serving public and private sector clients. Booz Allen exercised its option to acquire the remainder of Tracepoint's business after making an initial strategic investment in Tracepoint in January 2021. This transaction is part of a broader capital deployment strategy to accelerate Booz Allen's entry and advancement in critical technology areas. Terms of the agreement were not disclosed.

06:40 EDT Crescent Point Energy sees FY22 production 131,000-135,000 boe/d - Crescent Point announced its preliminary 2022 budget, which is expected to generate excess cash flow. Based on its initial budgeting process and the current outlook for commodity prices, Crescent Point is expecting to generate annual average production of 131,000-135,000 boe/d in 2022 based on development capital expenditures of $825M-$900M. Consistent with its capital allocation framework, the company's annual budget will continue to include a portion of capital allocated to long-term projects, such as decline mitigation, and various environmental initiatives. Crescent Point's preliminary 2022 budget is expected to generate significant excess cash flow, after dividends, of approximately $625M-$875M at $65/bbl - US$75/bbl WTI. Crescent Point has approximately 30% of its oil and liquids production currently hedged for 2022 and will continue add further protection in the context of commodity prices. The company will retain flexibility in its overall capital allocation as it formalizes its budget, which is expected to be released prior to the end of the year. Additional details on Crescent Point's 2022 program and other guidance information will be provided at that time.

06:38 EDT MiMedx reports data from late-stage musculoskeletal trials of mdHACM - MiMedx Group announced top-line results from two late-stage musculoskeletal clinical trials of the company's micronized dehydrated Human Amnion Chorion Membrane: a Phase 2B clinical trial for the treatment of Knee Osteoarthritis and a Phase 3 clinical trial for the treatment of Plantar Fasciitis. Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B clinical trial for KOA did not meet primary endpoints, but did reveal varied efficacy signals between patient cohorts evaluated pre- and post- a blinded interim analysis performed in mid-2019, prompting the company to plan for confirmatory efficacy studies for the KOA indication. The Phase 3 PF study did not meet its primary endpoint, and the company will not pursue a BLA for this indication at this time. Throughout both studies, the mdHACM product was found safe and well-tolerated. The company plans to meet with the FDA to thoroughly review the findings and determine the appropriate path forward toward the initiation of Phase 3 clinical trials in KOA. Based on the current analysis of the interim results for the Phase 2B clinical trial, the company now believes that two Phase 3 studies in KOA will be required to file a BLA and intends to provide an update for the timing of the filing, previously tentatively planned for late-2024 or early-2025, following review and discussion with the FDA.

06:34 EDT Alzamend Neuro initiates Phase I trial of AL001 - Alzamend Neuro announced that the first group of healthy participants have been dosed in a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer's disease. The Phase I first-in-human study is for the purpose of determining potential clinically safe and appropriate dosing for AL001 in future studies. AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer's disease.

06:32 EDT Trane to acquire Farrar Scientific in upfront transaction of $250M - Trane Technologies announced that it has signed an agreement to acquire Farrar Scientific, a leader in ultra-low temperature control for biopharmaceutical and other life science applications. Trane Technologies will acquire 100% of Farrar Scientific's assets, including its patented ultra-low temperature control technologies, a development and assembly operation in Marietta, Ohio, and a specialized team of engineers, sales engineers, operators, and technicians. Farrar Scientific personnel will join the Trane Technologies' Life Science Solutions team. This includes Scott Farrar, founder and chief technology officer of Farrar Scientific, who will serve as vice president of technology and innovation. Jim Vuksic, Farrar Scientific's president and CEO, will serve as an advisor to the team. The upfront transaction value is $250M, with a total transaction value of up to $365M inclusive of $115M in additional payout potential in 2025 tied to the attainment of key financial targets. The acquisition will be funded with available cash on hand, and is expected to be modestly accretive to EPS in the first three years. Additional details of the transaction were not disclosed and are not material. The transaction is expected to close in the fourth quarter, subject to regulatory approval and customary closing conditions.

06:18 EDT Matinas BioPharma reports 'positive' data from ongoing EnACT trial of MAT2203 - Matinas BioPharma announced positive efficacy and safety data from the first two cohorts of patients in the ongoing Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial of MAT2203 for the treatment of cryptococcal meningitis, which is being sponsored by the National Institute of Allergy and Infectious Diseases. Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity was 0.38, exceeding the prespecified primary endpoint threshold target of greater than0.20. Overall survival was greater than95% in 40 patients receiving MAT2203 in Cohort 2. All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first 10 weeks of antifungal treatment. Patients received MAT2203 for up to 6 weeks without kidney toxicity or electrolyte abnormalities attributable to MAT2203. DSMB unanimously recommends progression to Cohort 3; Enrollment has commenced. The company is preparing to engage with the FDA to review EnACT data as supportive of potential early approval of MAT2203 as a step-down therapy.

06:14 EDT TransUnion to acquire Neustar for $3.1B in cash - TransUnion has signed a definitive agreement to acquire Neustar, an identity resolution company with leading solutions in Marketing, Fraud and Communications, from a private investment group led by Golden Gate Capital and with minority participation by GIC. The acquisition expands TransUnion's powerful digital identity capabilities through the addition of Neustar's distinctive data and analytics, enabling consumers and businesses to transact online with greater confidence. Headquartered in Reston, Virginia, Neustar is expected to generate approximately $575M of revenue and $115M of Adjusted EBITDA in 2021. After integrating Neustar, TransUnion expects to accelerate growth through both material revenue synergies and increased participation in the fast-growing digital marketing and identity fraud marketplaces. The company anticipates material cost synergies from the combined companies, and expects the transaction to be accretive to Adjusted Diluted EPS beginning in 2023. Neustar's security business, which is excluded from the transaction, will become a Golden Gate Capital and GIC portfolio company following close. The transaction consideration is $3.1B in cash. The transaction is expected to close in Q4 2021 subject to the satisfaction of customary closing conditions and regulatory approvals.

06:11 EDT TPG Pace Tech Opportunities expected to close combination with Nerdy on 9/20 - TPG Pace Tech Opportunities announced that it expects all conditions to be met, including minimum cash proceeds, to complete its previously announced business combination with Nerdy, a platform for delivering live online learning. Based on the number of public shares submitted for redemption, the transaction is expected to raise more than $575M of gross proceeds from the TPG Pace Tech Opportunities trust proceeds combined with the private placement and forward purchase agreement proceeds. A quorum of shareholders has thus far voted in favor of all proposals presented in the proxy, including closing the business combination with Nerdy. Therefore, the company anticipates receiving stockholder approval at its Special Meeting of Stockholders scheduled for September 14, and expects to close the transaction on September 20. Upon closing, the combined company is expected to remain listed on the New York Stock Exchange with its common stock and warrants trading under the new ticker symbols, "NRDY" and "NRDY WS", respectively beginning September 21.

06:09 EDT Mattel launches Barbie Music Producer doll - Mattel announced Barbie Music Producer, a doll designed to introduce girls to an underrepresented career where women make up less than 3% of music producers and shine a light on the importance of women's stake in the industry. As the #1 global toy property and original girl empowerment brand, Barbie recognizes the barriers that impede girls from reaching their limitless potential and aims to level the playing field for girls as part of the Barbie Dream Gap Project. With over 200 careers and counting, Barbie is mixing it up as a music producer to show girls more role models in this space and encourage purposeful play through careers they may not be familiar with. Each music producer doll in this collection wears a graphic tee, trendy jeans, an iridescent crop jacket, platform boots and has colorful hair in four fun styles. The doll also comes with a sound mixing board, computer and headphone accessories to get the creativity and music going. Music producer Barbie is available today for $14.99 at major retailers and on Barbie.com.

06:04 EDT Leap Therapeutics announces DisTinGuish ORR data ahead of presentation - Leap Therapeutics announced the company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1, or DKK1, antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer, at the European Society for Medical Oncology, or ESMO, Congress, being held virtually on September 16-21. The company will host a conference call on Friday, September 17 to discuss preliminary results from the study. DKN-01 in combination with tislelizumab and chemotherapy demonstrated overall response rates, or ORR, as a first-line treatment for advanced G/GEJ cancer In the primary efficacy analysis, including all patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in DKK1-high patients as compared to a 56% ORR in DKK1-low patients In the overall intent to treat population, including those patients who did not receive a full cycle of therapy, the ORR was 60%, with 75% ORR in DKK1-high patients as compared to a 56% ORR in DKK1-low patients As of the date of the abstract, 13 patients had experienced a partial response, or PR, six patients had a best response of stable disease, or SD, one patient was non-evaluable for response, or NE, three patients were unable to complete a full cycle of therapy and two patients were pending their first tumor assessment. Of the 18 patients that had RNAscope DKK1 expression available for the abstract, 9 were DKK1-high and 9 were DKK1-low. Subsequent to the date of the abstract, the two patients who were pending their first scan for response to therapy were determined to have had PRs, and three additional patients were determined to have had DKK1-high tumors, each of whom experienced a PR. Further results will be presented at the ESMO Congress from September 16 to 21.

05:53 EDT Amerant Bancorp plans to effect clean-up merger, approves stock repurchase plan - Amerant Bancorp announced its intention to effect a clean-up merger, subject to shareholder approval, pursuant to which a subsidiary of the company will merge with and into the company. Under the terms of the merger, each outstanding share of Class B common stock will be automatically converted to 0.95 of a share of Class A common stock without any action on the part of the holders of Class B common stock; however, to the extent any shareholder, together with its affiliates, would own more than 8.9% of the outstanding shares of Class A common stock following the merger, such holder's shares of Class A common stock or Class B common stock, as the case may be, will be converted into shares of a new class of Non-Voting Class A common stock, solely with respect to holdings that would be in excess of the 8.9% limitation. The terms of the merger to be submitted for approval of the shareholders will include the creation of a new class of Non-Voting Class A common stock. Following the merger, no shares of Class B common stock will remain outstanding. In addition, all shareholders that would hold fractional shares as a result of the merger will receive a cash payment in lieu of such fractional shares. To the extent that following the merger any holder would beneficially own fewer than 100 shares of Class A common stock, such holder will receive cash in lieu of Class A common stock. The company expects to hold a special shareholders meeting to seek approval of the merger in early December. The company further announced that its board authorized a new share repurchase program, pursuant to which the company may purchase, from time to time, up to an aggregate amount of $50M of its shares of Class A common stock. Repurchases under the repurchase program may be made in the open market, by block purchase, in privately negotiated transactions or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. Repurchases of the company's shares of Class A common stock will depend upon market conditions, regulatory requirements, other corporate liquidity requirements and priorities and other factors as may be considered in the Company's sole discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. The repurchase program does not obligate the company to repurchase any particular amount of Class A common stock and may be suspended or discontinued at any time without notice. In addition, the board terminated the company's existing Class B common stock repurchase program, which was initially announced by the company in March.

05:35 EDT Baidu to begin public testing of Apollo Go robotaxi mobile platform in Shanghai - Baidu announced that it will begin public testing of Apollo Go in Shanghai, marking the fifth city where passengers have the ability to trial the robotaxi mobile platform. Baidu said it is the only company to offer this service in the three first-tier cities of Beijing, Guangzhou and Shanghai. The Shanghai operation will include 150 stations opened in phases throughout the city to provide users access to residential areas, commercial areas, offices and public transportation. Passengers can use the service from 9:30 a.m. to 11:00 p.m. every day of the week. This announcement comes on the heels of another milestone for Baidu Apollo - the expansion of Apollo Go to Tongzhou District in Beijing, where the service will enable residents and visitors of the suburb to experience travel in an autonomous vehicle. The first batch of routes in Tongzhou will cover a total of 22 stations- with a total distance over 31 miles, allowing for more than 100 trips every day. As of the end of August, Apollo L4 autonomous driving accumulated 8.7M test miles. Following the launch in Shanghai, Baidu plans to bring Apollo Go services to 25 more cities in the next three years, making autonomous driving a reality for 3M people in China.

05:27 EDT Hutchmed receives breakthrough therapy designation in China for amdizalisib - Hutchmed announced that the Center for Drug Evaluation of China's National Medical Products Administration, or NMPA, has granted breakthrough therapy designation, or BTD, to amdizalisib, a highly selective and potent PI3Kd inhibitor, for the treatment of relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma.

05:22 EDT Yamana Gold announces initial drill results at Wasamac project in Quebec - Yamana Gold announced initial drill results at its Wasamac project in the Abitibi-Temiscamingue Region of Quebec, Canada, confirming the presence of the Wasa Shear zone to the west of the main Wasamac zone and expanding the down-dip continuity of the Wasa Shear in a secondary zone known as Wildcat. These initial results further align with the objective to sustain 200,000 ounces per year of production at Wasamac and achieve a strategic mine life of more than 15 years, which, in turn, aligns with the potential to increase the company's average annual production in Quebec to approximately 500,000 ounces by 2028 through 2041. Consistent with the optimization strategy announced with the development decision on Wasamac on July 19, the company is advancing an exploration program that focuses on expanding the current mineral resource envelopes to depths below the established mineral resource and testing for mineralization in poorly explored gaps between mineralized zones. In addition, the exploration program will target the broader Wasamac property, including the adjacent Francoeur, Arntfield and Lac Fortune gold deposits and include an infill program to better delineate mining areas expected to be developed in the first three years of production. The company also provided an update on its generative exploration program, announcing the discovery of a high-grade gold-copper zone at the Lavra Velha project in Brazil and the expansion of massive sulphide copper, gold, and zinc mineralization over a greater than two-kilometer strike length at the Borborema project in Brazil. The generative exploration program is a key component of Yamana's overall organic growth strategy, designed to advance the company's most prospective properties and lay the foundation for the next generation of Yamana mines. The company's generative work is focused on its large land positions in mining-friendly jurisdictions in the Americas where Yamana already has producing mines and deep technical, geological, and operational expertise. This allows for the rapid advancement of the company's highest value projects while at the same time moving the most promising early-stage properties up the exploration pipeline. The generative exploration program thus complements and leverages from the low-capital organic growth strategy of the company, which delivers returns on investment while providing for future production growth at the company's existing operations and advancing projects. The main objectives of the generative program are to add new inferred mineral resources of at least 1.5M ounces of gold equivalent and on a longer-term basis advance at least one project to a mineral inventory that is large enough to support a mine plan demonstrating economics with annual gold production of 150,000 ounces per year for at least eight years.

05:13 EDT Elbit Systems awarded $56M in contracts to supply ASW capabilities - Elbit Systems announced that it was awarded contracts, in an aggregate amount of approximately $56M, to supply Anti-Submarine Warfare, or ASW, capabilities to the Navy of a country in Asia-Pacific. The contracts will be performed over a 12-month period. Under the contracts, Elbit Systems will provide the Seagull USVs configured to perform ASW missions and the Towed Reelable Active Passive Sonar, or TRAPS, systems. The Seagull USVs will integrate Helicopter/Ship Long-Range Active Sonars and will be equipped with the company's autonomous suite, Combat Management System and Satellite Communication capability. The TRAPS systems, which will be installed onboard the customer's corvettes, are low frequency variable-depth-sonars intended for detection, tracking and classification of submarines, midget submarines, surface vessels and torpedoes.

05:06 EDT Paysafe partners with bunq to provide cash services - Bunq, the app-based Dutch challenger bank, has partnered with Paysafe to provide customers with access to cash services. Customers who prefer to use cash in their daily lives can now use Paysafecash, one of Paysafe's eCash solutions, to conveniently add cash into their bunq accounts. The international roll-out of the partnership between Paysafe and bunq, which starts with 21 European countries, facilitates quick and secure cash deposits directly via the bunq mobile app: After selecting Paysafecash as the top up method in their app, the customer chooses how much cash to deposit into the account and generates a unique barcode for the transaction. The customer can then go to a nearby payment point, scan the barcode at the point of sales terminal and make the payment in cash. The deposited amount will show on the bunq balance within minutes. Paysafecash is available at around 190,000 payment points in 29 countries including the U.S. and Canada.